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Abstract
Mammographic screening (MS) and prophylactic surgery (PS) can potentially reduce cancer
risks in BRCA1/2 mutation families. The evaluation of these interventions is complicated both
by the presence of competing events and by their values changing over time. We propose a
competing risks model and provide cause-specific penetrance estimates to account for time-
varying covariates in the presence of competing events. A shared frailty model is specified
to account for familial residual dependence and is estimated to correct for the ascertainment
bias induced by the sampling of families through probands via an ascertainment corrected
likelihood approach. We evaluate the performance of the estimators for the parameters in the
model and the plug-in estimators for the penetrance functions via simulations. We apply our
proposed method to BRCA1/2 mutation carrier families recruited through the Breast Cancer
Family Registries and evaluate the effects of PS and MS on breast and ovarian cancer risks.
Keywords: competing risk model; time varying covariate; frailty; cancer screening; recur-
rent data; time-to-event data; family data.
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Chapter 1
Introduction
In this thesis, we propose a shared frailty model extended to competing risks framework
with time-varying covariates for data arising from family studies. We provide the cause-specific
cumulative incidence function also called, penetrance, to estimate age-specific risks of disease
with time-varying covariates in the presence of competing events. A shared frailty model is
specified to account for familial residual dependence and an ascertainment-corrected likeli-
hood is used to correct selection bias in family studies.
Our study is motivated by hereditary breast ovarian cancer (HBOC) families that experience
high risks of breast and ovarian cancers due to mutations in BRCA1/2 genes. BRCA1 and 2 are
tumour suppressor genes that produce proteins that help repair damaged DNA, keeping the
genetic material of the cell stable. A damaged BRCA gene can lead to increased risk of cancer,
particularly breast or ovarian cancer in women and, to a lesser extent, other cancers such as
prostate cancer in men. According to Petrucelli et al. (2016), for BRCA1/2 mutation carriers,
lifetime risk of breast cancer is from 38% to 87% while that of the general population is only
about 12% for women. Ovarian cancer risk is also significantly increased for mutation carriers.
Prevention and intervention such as mammographic screening (MS) and prophylactic surgery
(PS) can potentially affect the cancer risks in BRCA1/2 mutation positive families.
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Our proposed modelling approach is aimed to handle the following statistical challenges
arising from modeling HBOC family data: (1) the presence of competing risks, (2) familial
correlation and ascertainment bias of sampling families and (3) time-dependent nature of co-
variates such as MS and PS.
First, while women in HBOC families are at risk for both breast and ovarian cancers while
death from other causes than breast or ovarian cancer can preclude observing those cancers.
Thus, we treat breast, ovarian cancers and death as competing events. The occurrence of ovar-
ian cancer can alter the probability of breast cancer, or vice versa. For example, women affected
by ovarian cancer could undergo various treatment regimes such as oophorectomy or radiother-
apy treatment, which can potentially affect the risk of breast cancer. Therefore, modelling the
risk of breast cancer is susceptible to bias when ignoring the presence of ovarian cancer in the
risk set by treating the event as right censoring. In survival analysis, noninformative censoring
is an important assumption which states that the mechanism behind the censoring must be in-
dependent of the survival time of the subject. In other words, the distribution of right censoring
times bears no information on the distribution of the survival times. Subjects with censored
survival times have the same survival prognosis as those who are still in the study at any given
time, i.e., the censored subjects are at risk for the outcome regardless of the reason why they
were censored for the duration of the study. However, this assumption is often violated in
practice where the study population is exposed to other events referred to as competing events,
which alter the probability of experiencing the event of interest. For instance, it is common
practice to censor the patients who die before the occurence of the event of interest. These
right censored subjects do not have the same prognosis as those who are still followed because
subjects who die of other causes have a probability of zero to reach the event of interest. With-
out accounting for the competing risk of death, the incidence of the event will be overestimated
(eg. Kaplan Meier estimates) since subjects censored due to the death remain in the risk set.
This overestimation may be substantial with higher rate of occurence of the competing events
(Noordzij et al., 2013).
Third, the breast and ovarian cancer are rare among the general population and highly hered-
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itary, thus, family-based study is often designed to recruit higher risk individuals and their
family members than general population. This invokes the two necessities in our modelling
appoach: handling of the familial clustering among observations through frailty based model
and the correction for the sampling bias through ascertainment correction. Family data possess
an unobserved cluster effect which induces dependence among failure times in the same family.
Frailty model is commonly used to model clustered data for which a random effect, referred
to as frailty, is used to account for the variability in failure times within families. This random
effect acts in family level to generate the dependence among family members and measures the
effect of unobserved risk factors shared within the family.
Finally, most mutation carrier women opt for screening strategies rather than risk-reducing
mastectomy with the hope that, if a cancer develops, it will be detected at a curable state. These
screening strategies in women rely on a combination of monthly breast self-examination, clin-
ical breast examination, mammography and breast MRI. Relative risk estimates of these treat-
ments as well as prophylactic surgeries could help a woman making treatment decision e.g.
chemo-prevention decision or the use of oral contraceptives. As those variables change over
time, it is crucial to accurately incorporate them and evaluate their effects to minimize the mis-
specified exposure period. Because the subjects are often followed over a long time period,
treating these variables as time invariant covariates might induce bias in the modelling result
due to mispecified exposure time to the covariate effect. In this thesis, we suggest method-
ology to analyze their complex variation with time by incorporating the Permanent Exposure
(PE), Exponential Decay (ED) and Cox and Oakes (CO) functions for the effect of binary time
varying covariates.
1.1 Objectives
The objectives of our study are as follow:
1. Develop shared frailty competing risk models with time varying covariates to account
for the ascertainment bias and familial correlation;
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2. Evaluate and compare the performances of the three time varying covariate functions in
shared frailty competing risks models through a simulation study;
3. Derive the cumulative incidence function for an event of interest in the presence of time
varying covariates using the proposed shared frailty competing risk model;
4. Assess performances of the proposed models on the estimation of cumulative incidence
risk through a simulation study;
5. Estimate the risk of the first cancer (either breast or ovarian) in BRCA1/2 mutation pos-
itive families accounting for a woman’s screening history and the prophylactic surgery
treating them as time varying covariates using the proposed model.
1.2 Organization of the thesis
In Chapter 2, we provide a literature reviews on related topics including competing risk
models, the shared frailty model for clustered data, time varying covariates and ascertainment
bias. In Chapter 3 we develop a shared frailty competing risks model to account for three
different effects of time varying covariates and provide cause-specific penetrance accounting
for time-dependent covariates. In Chapter 4, we conduct a simulation study to evaluate our
proposed model for estimating the penetrances. In Chapter 5, we apply the proposed model to
data from BRCA1 and BRCA2 mutation positive families collected by the Breast Cancer Family
Registry. Possible future research and limitations are presented in Chapter 6.
Chapter 2
Literature Review
2.1 Competing risk models
Competing risk models are designed to extend the traditional survival models by consider-
ing the collection of mutually exclusive events. In some clinical settings, subjects are exposed
to more than one disease, which can potentially influence the occurrence of the disease of in-
terest. For instance, when analyzing peritoneal dialysis patients, the time to peritonitis episode
is of interest. However, before this episode, the patient might undergo death, kidney transplan-
tation or transfer to heamodialysis. These events are then competing for its first occurrence
where one occurrence can affect the probabilities of the others (Noordzij et al., 2013). In this
scenario, one might completely ignore competing events or simply right censor the subjects
who are affected by them. The latter approach is not to promising since it potentially violates
the non-informative censoring assumption, which states that censoring mechanism must be in-
dependent of the survival time of the subject. Then, the violation of the assumption induces the
bias in the risk estimation. As an example, suppose we right censor the patients who died be-
fore the occurence of the peritonitis episode, but assume these patients have the same prognosis
as the subjects still in the study. However, deceased subjects cannot be affected by peritonitis,
which means even though they contribute to the risk set, their probability of developing the
episode is 0 leading to the overestimation of its risk (e.g. Kaplan Meier estimates). According
5
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to Koller et al. (2012), 70% of the 50 articles in top journals neglected competing risk process
or imposed naive-approach even while their study populations were susceptible to competing
risks.
Methodologies to handle competing risks have been developed by several authors. Pren-
tice et al. (1978) proposed cause-specific hazard approach that modeled the hazard function
separately for each type of failure. The subdistribution hazard regression model introduced by
Fine and Gray (1999) has its significance in terms of one-to-one correspondence between its
hazard function for the specific event and the cumulative incidence of the same event, whereas
it is not viable in cause-specific approach. The mixture model by Larson and Dinse (1985) and
Ng and McLachlan (2003) involves fitting a more complex model which assumes multinomial
distribution for failure types. Their model expresses the failure time distribution in competing
risk data in terms of the marginal distribution of failutre type (multinomial logistic distribu-
tion) and the conditional distribution of time to failure, given the type of failure (proportional
hazard model). This mixture model assumes that an individual will fail from a particular risk,
chosen by a stochastic mechanism characterized by the marginal distribution of each failure
type (Ng and McLachlan, 2003). Lune and McNeil (1995) modified Cox regression to treat
the different types of failure jointly by augmenting the data using a duplication method. With
J failure types, the data would be duplicated J times, one row for each failure type. Each event
type is defined as an indicator variable that equals to 1 for event j and 0 for the remaining
J−1 entries. An unstratified or a stratified Cox regression could be applied on this augmented
dataset, depending on whether the assumption of proportional hazards holds. The unstratified
method assumes that the hazard functions for different failure types are proportional, whereas
the stratified method allows for different baseline hazards in each failure type. The primary ad-
vantage of this procedure is that it facilitates direct comparisons between different event types.
This thesis is based on the cause-specific approach due to the ease of incorporating cause-
specific frailty and TVCs. The cause-specfic hazard approach was introduced by Prentice et al.
(1978). Cause-specific hazard function, h j(t), is defined as the instantaneous rate of occurrence
of the specific event, within a very short period of time, t and t+dt, given that the subject has
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survived by time t from all the competing events until time t. Let T o and C be the time to the
first event time and the right censoring time, respectively. Let δ ∈ {1, . . . ,J} be the type of
the first observed event time among J competing events and δ = 0 if right censored. Define
T = min(T o,C). Then, the cause-specific hazard for event j, j = 1, ...,J, is defined as,
h j(t) = lim
dt→0
1
dt
P(t ≤ T < t+dt,δ = j|T ≥ t).
The corresponding cause-specific cumulative hazard, H j(t) is obtained by integrating the
cause-specific hazard until time t, H j(t) =
∫ t
0 h j(u)du. Then, the probability of surviving from
all the possible events until time t is defined as
S(t) = P(T ≥ t) = exp{− J∑
j=1
∫ t
0
h j(u)du
}
.
Finally, the cause-specific cumulative incidence for event j is defined as
Fj(t) = P(T ≤ t,δ = j) =
∫ t
0
h j(u)S(u)du.
The idea behind this relation can be explained as follows. The probability of the given event
j occurring at any time u is determined by the product of the two terms inside the integral: One
is the probability that the subject has not experienced any event before time u indicated by
overall survival function S(u) = P(T ≥ u) and the other is the probability of event j occurring
at time u given that no event has happened. Since the cause-specific cumulative incidence func-
tion associates all the possible causes in its formulation, there is no one-to-one correspondence
between cause-specific hazard and its cause-specific cumulative incidence (Geskus, 2016). For
this reason, the way that covariates are associated with cause-specific hazard and cause-specific
cumulative incidence may not coincide in the regression setting.
Nonparametric estimation of the cause specific cumulative incidence can be obtained by the
method originally aimed for estimating transition probability of multi-state model introduced
by Aalen and Johansen (1978) as
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Fˆj
AJ
(t) = ∑
Zi≤t
Sˆ(Zi)hˆ j(Zi),
where Zi is the ith event time among the uniquely ordered M event times, {Z1,Z2, ...,ZM}
and hˆ j(Zi) is the cause-specific hazard at each observed discrete time Zi and obtained by the
number of subjects with event j at Zi, divided by the total number of subjects at risk. Sˆ(Zi) is
the classical Kaplan-Meier estimate of the overall survival obtained by simply combining all
the event types.
Southern et al. (2006) and Tai et al. (2001) compared the naive Kaplan Meier (KM) estima-
tors under three censoring approaches in the presence of competing risks: ‘censor all’, ‘censor
death only’, and ‘ignore all’. In the ‘censor all’ approach, subjects are censored with the oc-
currence of a competing event in advance of the event of interest. In the ‘censor death only’
approach, subjects are censored if they experience death before the event of interst. Lastly, the
‘ignore all’ approach only censors subjects who are truly lost to follow-up. Upward bias in
cumulative incidence of event of interest was found to be the most significant in ‘censor all’
method followed by ‘censor death only’ and ‘ignore all’ methods. It was clearly shown that
all of the naive KM estimators with different censoring approaches overestimated the cause-
specific cumulative incidence. Additionally, Tai et al. (2001) showed that estimates of the
cause-specific cumulative incidence from the cause-specific hazard model and the modified
Cox method by Lune and McNeil (1995) were highly comparable.
Shifting our focus on the regression model to incorporate the covariate effects, suppose we
have a vector of covariates X . The cause-specfic hazard model for event j given X is defined
as
h j(t|X ) = h0 j(t)exp
{
β Tj X
}
,
where β j is the vector of regression coefficients associated with event j and h0 j(t) is the base-
line hazard function, which can be modeled parametrically in specific functional form. Several
common baseline hazard models are specified in Table 2.1. We can also subdivide time into
reasonably small intervals and assume that the baseline hazard is constant in each interval,
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leading to a piece-wise semi-parametric model. A baseline hazard function needs not to be
specified if we rely on the partial likelihood function on model fitting focusing only on the
estimation of regression parameters.
No additional assumption on the dependence among competing events is required to esti-
mate cause-specific hazard (Prentice et al., 1978, Kalbfleisch and Prentice, 2002). Standard
techniques to fit traditional Cox proportional hazard model can be used to fit the cause-specific
hazard model for each competing event. The covariate effect has an interpretation on the cause-
specific hazard.
Table 2.1: Several possible choices of baseline hazard function
Distribution hazard h0 j(t) cumulative hazard H0 j(t)
Weibull ρ jλ j(λ jt)ρ j−1 (λ jt)ρ j
Log-logistic ρ jλ j(λ jt)
ρ j−1
1+(λ jt)
ρ j log{1+(λ jt)ρ j}
Gompertz λ jeρ jt
λ j
ρ j (e
ρ jt−1)
2.2 Frailty models for clustered time-to-event data
Clustered time-to-event data often arise in clinical research. For instance, in multicenter
clinical trials, patients in each center could potentially share common factors exclusive to their
center, so their clinical outcomes could be similar. Another example arises from family studies
where the ages at onset of disease are correlated among family members. Multiple records ob-
served from the same individual can be also viewed as clustered failure times. It is well noted
that inferences ignoring this cluster effect are potentially misleading; a misspecified model can
lead to underestimation of the covariate coefficients (Keilding et al., 1997). Lee et al. (1992)
have shown that it is still possible to obtain consistent and asymptotically normal estimators of
covariate coefficients in the standard Cox regression ignoring cluster effect. However, corre-
sponding variance-covariance estimators is not valid due to the dependence among members
in the same cluster. Approaches to obtain valid variance-covariance estimators accounting
for cluster effect are discussed by Lee et al. (1992) and Spiekerman and Lin (1998). How-
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ever, when the interest lies in obtaining the cluster effect, dependence structure between failure
times must be modelled. Shared frailty models and copula models are popular choices in this
situation. Similarities and differences between frailty and copula models were discussed by
Goethals et al. (2008). Considering the case of two subjects in each cluster, the joint survival
function of the two failure times is modeled via a function, called copula, which connects the
marginal survival functions of the two failure times. On the other hand, the frailty based model
shares a random variable, also called frailty, within a cluster. The frailty variable has a mul-
tiplicative effect on the hazard function. Conditional on the frailty term, failure times within
a cluster are assumed to be independent. Then, a joint survival function can be obtained by
integrating out the frailty.
2.2.1 Shared frailty model in non-competing risks setting
The frailty model was introduced by Vaupel et al. (1979) in survival model framework to
account for the unobserved heterogeneity in study population. Furthermore, Clayton (1978),
Hougaard (1984) and Oakes (1982) extended the frailty model to account for the unobserved
heterogenity shared within clusters introducing parametric gamma frailty distribution.
Let X fi be the vector of covariates for the subject i in cluster f and z f be the shared frailty
for cluster f . This shared frailty acts as a multiplicative factor on the the hazard under Cox
regression model as
h fi(t|X fi,z f ) = h0(t)z f exp(β TX fi),
where h0(t) is unspecified baseline hazard. Frailties z f are assumed to be independently and
identically distributed random variables. For the distribution of frailty, log-normal, gamma,
or inverse Gaussian are the popular choices (Duchateau and Janssen, 2008). We continue
our discussion with one parameter gamma distribution proposed by Hougaard (2000) with
shape parameter k and scale parameter 1/k, z f ∼ Gamma(k,1/k) to take an advantage of its
mathematical simplicity. Its density function follows
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g(z f ) =
zk−1f e
−kz f
k−kΓ(k).
Under this specification, random variable z f has mean of 1 and the variance of 1/k. Thus,
the smaller value of k induces the stronger within-cluster dependence. Since we do not observe
the frailty variable in practice, we obtain marginal distribution of the failure times by integrat-
ing out z f in the conditional distribution using the Laplace transform of the frailty distribution.
When k→ ∞, it is equivalent to the independent model and the hypothesis test H0 : 1/k = 0
can be constructed using Likelihood Ratio (LR) statistics. In this case, the null hypothesis
1/k = 0 is on the boundary of the parameter space and the distribution of LR test-statistics has
a 50:50 mixture of a chi-square with no degrees of freedom and a chi-square with one degree
of freedom (Self and Liang, 1987). k→ ∞ means z f = 1 and frailty effects are not important.
Kendall’s τ , which is a non-parametric measure of correlation, is related to the frailty parame-
ter k such that τ = 11+2k (Munda et al., 2012). Values of τ close to 1 indicate higher dependence
between failure times within clusters.
2.2.2 Shared frailty model in competing risk setting
So far our discussion was restricted to the clustered survival data under the non-competing
risk setting that accounts for the dependence of failure times of the one event type within a
cluster. In competing risk setting, dependence of the failure times could be different for dif-
ferent competing events. Gorfine and Hsu (2011) and Lai et al. (2017) discussed the methods
for modelling the dependence structure between the random frailty variables assigned for each
event type. Restricting our attention to the methodologies relevant to the cause-specific hazard
model framework, Gorfine and Hsu (2011) proposed multivariate normal distribution between
frailty variables.
We now denote z f = {z f1, ...,z fJ} as the vector of random frailty variables in cluster f for
J competing events. Gorfine and Hsu (2011) proposed a competing risk model where cause-
specific hazard follows
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h fi j(t|X fi,z f j) = limdt→0
1
dt
P(t ≤ Tfi < t+dt,δ fi = j|Tfi ≥ t,X fi,z f j)
= h0 j(t)exp(β Tj X fi + z f j),
for j = 1, ...,J, where β 1, ...,β J are the vectors of cause-specific regression coefficients and
h01(·), ...,h0J(·) are cause-specific baseline hazard functions. Importantly, Gorfine specified
the dependence structure of the z f with
z f = {z f1, ...,z fJ} ∼ NJ(µ ,Σ),
where NJ(µ ,Σ) is the multivariate normal distribution with J-dimensional mean vector µ and
J× J covariance matrix. Estimation of Σ gives insight to the dependence of failure times of
J competing events between subjects in the same cluster. For instance, in case of bivariate
normal distribution accounting for two competing events, Σ can be defined as:
Σ=
 σ21 ρ12σ1σ2
ρ12σ1σ2 σ22
 ,
where the correlation coefficient ρ12 measures the dependence between the frailty terms z f1 and
z f2 . If ρ12 = 0, the model degererates to the model with independent frailties. In other words,
z f j , j = 1, ...,J, are independent between different events. Lai et al. (2017) proposed a bivari-
ate normal random effects competing risk model under two competing events. It is similar to
Gorfine’s model but they used iterative numerical procedure to estimate the model parameters
under generalized linear mixed model framework. In the first step, they obtain estimates of
covariate coefficients and conditionally fixed random cluster effects for a given variance com-
ponents parameters by maximizing partial log-likelihood. In the second step, they obtained
restricted maximum likeliehood estimates of variance components parameters in bivariate nor-
mal distribution by solving the estimating equations.
Lee et al. (2017) discussed similar approach but varying degree of dependence structure.
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Lee et al. (2017) assumed each cluster f shares the same frailty variable z f for all the competing
events. Under this specification, jth cause-specific hazard becomes
h fi j(t|X fi,z f ) = h0 j(t)z f exp
{
β Tj X fi
}
.
In this case, z f accounts for the unobserved cluster-level effect not specific to event j but
all the possible events. They also extended this framework to handle missing cause of failure
using hierarchical likelihood.
2.3 Time varying covariates
In analyzing time to event data, Cox proportional hazard model has the advantage of ease
of incorporation on the effect of covariates as multiplicative factor to the unspecified baseline
hazard. Time-fixed or time invariant covariate (TIC), which is measured at baseline, does not
change over the study period. However, in practice, it is plausible to assume that covariate val-
ues change over time due to, for instance, drug dosages or the number of screenings which vary
over follow-up period. Cox model allows us to incorporate such time varying covariates (TVC)
denoted as X(t) based on the modelling of hazard function h(t). Hazard function describes the
instantaneous risk of the event of the interest at time t given that the subject has survived until
that time. As we condition on the survival until time t, covariate value can be measured at any
time between 0 and t.
In clinical setting, assessing the effect of TVC is important especially when the follow-up
duration is long. For example, consider binary variable for certain treatment occurring later
period of the follow-up duration. If we code this variable as TIC, treatment exposure duration
becomes much longer than actual exposure. We lose information that the subject was actually
absent of its effect for the most of the follow-up time. Therefore, modelling results can be
potentially misleading due to the bias incurred. Daniel et al. (2015) quantified bias in Cox re-
gression for the study of risk of spontaneous abortion following nonsteroidal anti-inflammatory
drug exposure. When the exposure of the drug was treated as TIC, the drug effect was statis-
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tically significant but this effect was not significant under TVC setting. In addition, the effects
of all the other drugs in this study were biased in varying extent depending on the length of
misspecified exposure period. Our analysis on the effect of the BO and MS in Chapter 5 is
relevant to this issue since most of the patients have relatively long follow-up duration.
Suppose subjects received treatment at time tx during the follow-up. The TVC can be de-
fined as X(t, tx) = 0 for t < tx and X(t) = 1 for t ≥ tx. Then, the effect of treatment in Cox model
is multiplicative to the baseline hazard such that h0(t)eβX(t,tx). This type of TVC is referred
to as Permanent Exposure (PE) (Keown-Stoneman et al., 2018) as its effect stays constant at
β as t → ∞. The effect of the PE does not change over time t since the treatment time tx. In
other words, the hazard of a subject who received treatment recently does not differ from that
of a subject who received the treatment a long time in the past. This assumption may not be
plausible in many real world applications. One of the possible resolutions to this problem is
suggested by Cox and Oakes (1984). They proposed the formulation of a TVC effect which
decays over time with the rate parameter η and the additional parameter η0 that measures the
converged effect of TVC. Under this setting, the corresponding hazard function follows as
h(t|θ ) =

h0(t) if t < tx
h0(t)exp
{
η0+βe−η(t−tx)
}
if t ≥ tx.
In this formulation, the effect of the TVC on baseline hazard decreases over time with the
rate of η and converges to η0 as t → ∞. Subjects who received the treatment recently are
under stronger effect of the treatment than those who received the treatment further in the
past. Cox and Oakes noted multiple local maxima may exist in the partial likelihood function.
As a simplication of the Cox and Oakes model with η0 = 0, Keown-Stoneman et al. (2018)
suggested Exponential Decay (ED) model as
h(t|θ ) =

h0(t) if t < tx
h0(t)exp
{
βe−η(t−tx)
}
if t ≥ tx.
Under this model, the effect of TVC converges to 0 as t → ∞. They also provided the
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method to generate data under this model and performed a hypothesis test for H0 : η = 0
against H1 : η ≥ 0 using likelihood ratio test. When η = 0, this model is equivalent to the
permanent exposure model. Figure 2.1 graphically displays the effects of three TVC models.
Figure 2.1: Effect of time-varying covariate over time in Permanent Exposure (PE), Expo-
nential Decay (ED) and Cox and Oakes (CO) models given tx = 35, β = 1.5, η0 = 0.5 and
η1 = 0.3.
2.4 Ascertainment bias and ascertainment corrected likeli-
hood
Ascertainment bias in family studies arises due to the way individuals were selected. They
were only recruited via having high risk scores depending on familial disease history or mu-
tation carrier status in genes related to the disease. Therefore, collected individuals do not
represent the general population. Ignoring this selection procedure will incur the bias on the
estimation of the model parameters such as relative risk for the mutation carrier and non-carrier
and penetrance function. Gong and Whittemore (2003) discussed population and clinic based
study designs which are distinguished by their inclusion criteria. In population based design,
families are ascertained via an individual identified as affected or mutation carrier, where this
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individual is referred to as the proband. In clinic based design, multiple family members must
be affected for the study entry. Choi et al. (2008) developed the ascertainment corrected likeli-
hood methods for population- and clinic-based family designs and evaluated performances of
study designs on the estimation of penetrance and relative risk via a simulation study.
Suppose we have n independent families and family f , f = 1, ...,n has n f members. Ascer-
tainment corrected likelihood has a general form:
LC =
n
∏
f=1
L f
A f
,
where L f is the likelihood contribution of family f and A f is the probability of the family being
ascertained.
Chapter 3
Statistical Models
In this chapter, we develop the shared frailty competing risk model with Time Varying Co-
variates (TVC) and explain the inference procedure. In Section 3.1, we construct shared frailty
competing risk model with TVC. In Section 3.2, we speculate about likelihood construction
with ascertainment correction. In Section 3.3, we derive cause-specific penetrance function
with TVC. We discuss variance estimation procedure for cause-specific penetrance and covari-
ate coefficients in Section 3.4.
3.1 Shared frailty competing risk model with time-varying
covariates
Consider n independent families, with family f , f = 1, . . . ,n, having n f members. For
family member i of the family f , let T ofi and C fi be the time to the first event time and the
right censoring time, respectively. Let δ fi ∈ {1, . . . ,J} be the type of the first observed event
time among J competing events and δ fi = 0 if right censored. Define Tfi = min(T ofi ,C fi). Let
X fi be the vector of covariates which consist of time invariant and time varying covariates for
individual i in family f . Finally, we denote z f j as the shared frailty specific to the event j within
family f . Conditional on the vector of covariates X fi and the cause-specific familial frailty z f j ,
we assume the cause-specific hazard function for event j for individual i from family f follows
17
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a proportional hazards regression model
h fi j(t|X fi,z f j) = limdt→0
1
dt
P(t ≤ Tfi < t+dt,δ fi = j|Tfi ≥ t,X fi,z f j)
= h0 j(t)z f je
β Tj X fi ,
(3.1)
where h0 j is the baseline hazard function and β j is the vector of the covariate effects related to
event j. The corresponding jth cause-specific cumulative hazard function is defined as
H fi j(t|X fi,z f j) =
∫ t
0
h fi j(u|X fi,z f j)du
= H0 j(t)z f je
β Tj X fi ,
(3.2)
where H0 j is the cumulative hazard function for event j.
By the standard theory of competing risks, given the covariates and frailty, we define the
conditional cumulative hazard function H and survival function S:
H fi(t|X fi,z f j) =
J
∑
j=1
H fi j(t|X fi,z f j)
S fi(t|X fi,z f j) = exp{−
∫ t
0
J
∑
j=1
h fi j(u|X fi,z f j)du}
= exp{−H fi(t|X fi,z f j)},
(3.3)
where these are overall quantities across all competing events.
We implement time varying covariates (TVC) into the shared frailty competing risks model
in equations (3.1) to (3.3). For some covariates, such as individual BRCA1/2 mutation status,
they are time independent. However, for some covariates, such as surgery or screening vari-
ables which occur at certain age, it is plausible to assume that its effect might change over time.
Without loss of generality, suppose X fi includes a time varying covariate X fi(t, tx) and a time
invarying covariate G fi . We assume that X fi(t, tx) = 0 at t < tx and 1 at t ≥ tx, where tx is the
time that change in value of time varying covariate occured. Then, the effect of the TVC that
changes over time, denoted by g(·), can be described in three different structures: PE, ED, and
CO as follows,
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g(X fi(t)) =

0 if t < tx (PE,ED,CO)
β if t ≥ tx (PE)
βexp
{−η(t− tx)} if t ≥ tx (ED)
βexp
{−η(t− tx)}+η0 if t ≥ tx (CO) ,
where for time t ≥ tx, the effect of TVC stays at β for PE, whereas it starts to decrease with
a rate of η to 0 for ED or to η0 for CO. Then, we can specify jth cause-specific hazard and
cumulative hazard function with TVC and TIC as
h fi j(t|X fi,z f j) = h0 j(t)z f jexp
{
g(X fi(t, tx))+α jG fi
}
.
H fi j(t|X fi,z f j) =
∫ t
0
h0 j(u)z f jexp
{
g(X fi(u, tx))+α jG fi
}
du,
where G fi is the TIC and α j is the corresponding cause-specific covariate coefficient for event j.
For simplicity, omitting the terms related to TIC and the shared frailty term, the cause-specific
hazard can be specified for PE, ED and CO as
h fi j(t|X fi) =

h0 j(t) if t < tx (PE,ED,CO)
h0 j(t)exp
{
β j
}
if t ≥ tx (PE)
h0 j(t)exp
{
β je−η j(t−tx)
}
if t ≥ tx (ED)
h0 j(t)exp
{
β je−η j(t−tx)+η0 j
}
if t ≥ tx (CO) .
H fi j(t|X fi) =

H0 j(t) if t < tx (PE,ED,CO)
H0 j(tx)+
(
H0 j(t)−H0 j(tx)
)
exp
{
β j
}
if t ≥ tx (PE)
H0 j(tx)+
∫ t
tx h0 j(u)exp
{
β je−η j(u−tx)
}
du if t ≥ tx (ED)
H0 j(tx)+
∫ t
tx h0 j(u)exp
{
β je−η j(u−tx)+η0 j
}
du if t ≥ tx (CO) .
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where β j,η j and η0 j are the cause-specific TVC effect parameters for event j. Numerical
integration is required for computing cumulative hazard for ED and CO since no closed form
exists.
3.2 Likelihood construction with ascertainment correction
Let θ = {h0 j(.), β j, k j, j = 1, . . . ,J} be the vector of parameters involved in the model,
which consists of baseline parameters for specifying baseline hazard functions, regression co-
efficient vector β j and frailty parameter k j for each competing event j = 1, ...,J. Then, the
likelihood of the data from n families can be constructed simply by the product of the likeli-
hoods of all families.
L(θ ) =
n
∏
f=1
L f (θ ).
Under the shared frailty competing risk model framework, the likelihood for family f is
obtained by integrating over the frailty distribution:
L f (θ ) =
n f
∏
i=1
∫ ∞
0
· · ·
∫ ∞
0︸ ︷︷ ︸
J
{ J
∏
j=1
h fi j(t fi|X fi,z f j)I(δ fi= j)
}
S fi(t fi|X fi,z f )g(z f1) . . .g(z fJ)dz f1 . . .dz fJ .
(3.4)
To compute the integrals, we utilize Laplace transform φ(·) of the frailty distribution g(z f j)
and its dth derivative, φ(·)(d), which have the following expressions
φ(s) =
∫ ∞
0
e−szg(z)dz
φ(s)(d) = (−1)d
∫ ∞
0
zde−szg(z)dz.
(3.5)
With Gamma frailty distribution, they have closed form expressions:
φ(s) =
(
1+
s
k
)−k
φ(s)(d) = (−1)d (k+d−1)!
k!kd−1
(
1+
s
k
)−k−d
.
(3.6)
With the simple case of only 2 competing events, J = 2, which can be easily generalized to
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any number of J, the likelihood for family f can be obtained, omitting X fi after the first line
for simplicity:
L f (θ ) =
∫ ∞
0
∫ ∞
0
n f
∏
i=1
{ 2
∏
j=1
h fi j(t fi|X fi,z f j)I(δ fi= j)
}
exp
{
−
2
∑
j=1
H fi j(t fi|X fi,z f j)
}
g(z f1)g(z f2)dz f1dz f2
=
∫ ∞
0
∫ ∞
0
n f
∏
i=1
{ 2
∏
j=1
(
z f jhi j(t fi)
)I(δ fi= j)}exp{− 2∑
j=1
z f jHi j(t fi)
}
g(z f1)g(z f2)dz f1dz f2
=
n f
∏
i=1
2
∏
j=1
hi j(t fi)
I(δ fi= j)
∫∫
z
d f1
f1
z
d f2
f2
exp
{
− z f1
n f
∑
i=1
Hi1(t fi)− z f2
n f
∑
i=1
Hi1(t fi)
}
g(z f1)g(z f2)dz f1dz f2
=
n f
∏
i=1
2
∏
j=1
hi j(t fi)
I(δ fi= j)
∫
z
d f2
f2
exp
{− z f2 n f∑
i=1
Hi2(t fi)
}∫
z
d f1
f1
exp
{− z f1 n f∑
i=1
Hi1(t fi)
}
g(z f1)dz f1g(z f2)dz f2
=
n f
∏
i=1
2
∏
j=1
hi j(t fi)
I(δ fi= j)(−1)−d f1φ (d f1)
( n f
∑
i=1
Hi1(t fi)
)∫
z
d f2
f2
exp
{− z f2 n f∑
i=1
Hi2(t fi)
}
g(z f2)dz f2
=
n f
∏
i=1
2
∏
j=1
hi j(t fi)
I(δ fi= j)(−1)−d f1φ (d f1)
( n f
∑
i=1
Hi1(t fi)
)
(−1)−d f2φ (d f2)
( n f
∑
i=1
Hi2(t fi)
)
=
n f
∏
i=1
2
∏
j=1
hi j(t fi)
I(δ fi= j)
2
∏
j=1
(k j+d f j −1)!
k j! · k
d f j−1
j
(
1+
∑
n f
i=1Hi j(t fi)
k j
)−k j−d f j
,
(3.7)
where d f j is the number of family members affected by event j. Furthermore, to correct for
the ascertainment bias, we implement ascertainment corrected likelihood approach (Choi et
al., 2008). Families are ascertained via the probands (indexed as p) who are affected by their
age at examination (a fp). For each family f , we divide the L f (θ ) by the probability of the
proband being ascertained by her age at examination. Then, this probability is the conditional
cumulative incidence of events that qualify for ascertainment by a fp , that is A f (θ ) = P(Tfp ≤
a fp |X fp). Therefore, ascertainment corrected likelihood of data follows
LC(θ ) =
n
∏
f=1
L f (θ )
A f (θ ).
Recalling equations (3.3), (3.5) and (3.6), we derive this ascertainment correction term as,
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A f (θ ) = 1−S fp(a fp|X fp)
= 1−
∫
· · ·
∫ ∞
0
S fp(a fp|X fp,z f )g(z f1) . . .g(z fJ)dz f1 . . .dz fJ
= 1−
∫
· · ·
∫ ∞
0
exp
(
−
J
∑
j=1
z f jH fp j(a fp|X fp)
)
g(z f1) . . .g(z fJ)dz f1 . . .dz fJ
= 1−
J
∏
j=1
φ
(
H fp j(a fp|X fp)
)
= 1−
J
∏
j=1
(
1+
H fp j(a fp|X fp)
k j
)−k j
.
(3.8)
Then combining results from (3.7) and (3.8), we specify the ascertainment corrected likeli-
hood for all the families:
LC(θ ) =
n
∏
f=1
∏
n f
i=1∏
J
j=1
{
h fi j(t fi|X fi)
}I(δ fi= j)×∏Jj=1 (k j+d f j−1)!
k j!k
d f j
−1
j
(
1+ ∑
n f
i=1H fi j(t fi |X fi)
k j
)−k j−d f j
1−∏Jj=1
(
1+
H fp j(a fp |X fp)
k j
)−k j .
Maximum likelihood estimators of the parameters are obtained by maximizing the following
ascertainment-corrected log-likelihood,
`C(θ ) =
n
∑
f=1
logL f (θ )−
n
∑
f=1
logA f (θ )
=
n
∑
f=1
{ n f
∑
i=1
J
∑
j=1
I(δ fi = j)logh fi j(t fi|X fi)
}
+
n
∑
f=1
{ J
∑
j=1
log((k j+d f j −1)!)− log(k j!)− (d f j −1)log(k j)
− (k j+d f j)log
(
1+
∑
n f
i=1H fi j(t fi|X fi)
k j
)}
−
n
∑
f=1
log
(
1−
J
∏
j=1
(
1+
H fp j(a fp|X fp)
k j
)−k j)
.
(3.9)
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3.3 Cause-specific penetrance function with time-varying co-
variates
Our main interest is to estimate the jth cause-specific cumulative incidence function Fj(·)
or cause-specific penetrance. Conditional on the random frailty variable z f j , the cause-specific
penetrance is expressed as:
Ffi j(t|X fi,z f j) = P(Tfi ≤ t,δ fi = j|X fi,z f j)
=
∫ t
0
h fi j(u|X fi,z f j)S fi(u|X fi,z f j)du
=
∫ t
0
h fi j(u|X fi,z f j)exp{−
J
∑
j=1
H fi j(u|X fi,z f j)}du.
Since z f j is not observable, we obtain the marginal cause-specific penetrance function by in-
tegrating over the frailty distribution g(z f j). The marginal cause-specific cumulative incidence
function for event j is obtained in the presence of J competing events for individual i in family
f only given the vector of covariates X fi:
Ffi j(t|X fi) =
∫
· · ·
∫
J
∫ t
0
h fi j(u|X fi,z f j) ·S fi(u|X fi,z f j) ·g(z f1) . . .g(z fJ) ·du ·dz f1 . . .dz fJ .
On the simplest case with only 2 competing events, J = 2, the cause-specific penetrance
from cause 1, j = 1, omitting X fi for simplicity, can be expressed under z f j ∼ Gamma(k j, 1k j ):
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Ffi1(t|X fi) =
∫ ∞
0
∫ ∞
0
∫ t
0
h fi1(u|z f1)S fi(u|z f1,z f2)g(z f1)g(z f2)dudz f1dz f2
=
∫ ∞
0
∫ ∞
0
∫ t
0
h fi1(u)z f1exp
{
−H fi1(u)z f1−H fi2(u)z f2
}
g(z f1)g(z f2)dudz f1dz f2
=
∫ t
0
h fi1(u)
∫∫
z f1exp
{−H fi1(u)z f1−H fi2(u)z f2}g(z f1)g(z f2)dz f1dz f2du
=
∫ t
0
h fi1(u)
∫
exp
{
−H fi2(u)z f2
}∫
exp
{
−H fi1(u)z f1
}
g(z f1)dz f1g(z f2)dz f2du
=
∫ t
0
h fi1(u) ·−φ (1)
(
H fi1(u)
)∫
exp
{
−H fi2(u)z f2
}
g(z f2)dz f2du
=
∫ t
0
h fi1(u)
(
1+
H fi1(u)
k1
)−k1−1(
1+
H fi2(u)
k2
)−k2
du,
(3.10)
where we utilize Laplace transform φ(·) of the frailty distribution g(z f j) and its dth derivative,
φ(·)(d), similarly to the equations (3.7) and (3.8). Furthermore, we derive cause-specific pen-
etrance function with TVC for the shared frailty competing risks model presented in (3.10).
On the simplest case with only 2 competing events, J = 2, the cause-specific penetrance from
cause 1, j = 1, for individual i in family f follows
Ffi1(t|X fi(t, tx)) =
∫ t
0
h fi1(u|X fi(u, tx))
(
1+
H fi1(u|X fi(u, tx))
k1
)−k1−1(
1+
H fi2(u|X fi(u, tx))
k2
)−k2
du.
(3.11)
If t < tx, regardless of the structures of X fi(t, tx), equation (3.11) becomes
Ffi1(t|X fi(t)) =
∫ t
0
h01(u)
(
1+
H01(u)
k1
)−k1−1(
1+
H02(u)
k2
)−k2
du.
If t ≥ tx, equations (3.11) under PE, ED and CO follow respectively
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Ffi1(t|X fi(t, tx)) =
∫ t
0
h01(u)exp{β1}
×
(
1+
H01(tx)+(H01(u)−H01(tx))exp{β1}
k1
)−k1−1
×
(
1+
H02(tx)+(H02(u)−H02(tx))exp{β2}
k2
)−k2
du, (PE)
Ffi1(t|X fi(t, tx)) =
∫ t
0
h01(u)exp
{
β1e−η1(u−tx)
}
×
(
1+
H01(tx)+
∫ u
tx h01(s)exp
{
β1e−η1(s−tx)
}
ds
k1
)−k1−1
×
(
1+
H02(tx)+
∫ u
tx h02(s)exp
{
β2e−η2(s−tx)
}
ds
k2
)−k2
du, (ED)
Ffi1(t|X fi(t, tx)) =
∫ t
0
h01(u)exp
{
β1e−η1(u−tx)+η01
}
×
(
1+
H01(tx)+
∫ u
tx h01(s)exp
{
β1e−η1(s−tx)+η01
}
ds
k1
)−k1−1
×
(
1+
H02(tx)+
∫ u
tx h02(s)exp
{
β2e−η2(s−tx)+η02
}
ds
k2
)−k2
du, (CO)
where β1 and β2 are the cause-specific TVC effect coefficients, η1 and η2 are the cause-
specficic TVC decay rate parameters and η01 and η02 are the cause-specific TVC decay con-
vergence parameters for event 1 and 2, respectively.
3.4 Variance estimation
Let θ be the vector of the parameters which consists of baseline parameters for specify-
ing baseline hazard functions, regression coefficients and frailty parameters. The variance-
covariance matrix of θˆ is estimated using a robust sandwich variance estimator,
Var(θˆ ) = Io(θ )−1J(θ )Io(θ )−1,
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where Io(θ ) is the observed information matrix and J(θ ) is the expected information matrix.
They can be obtained by
Io(θ ) =− ∂
2`C(θ )
∂θ T∂θ
J(θ ) =UT (θ )U(θ )
U(θ ) =∑
f
∂ logL f (θ )
∂θ
−∑
f
∂ logA f (θ )
∂θ
where `C(θ ) is the ascertainment corrected log-likelihood of the data as presented in the equa-
tion (3.9), logL f (θ ) is the log-likelihood contribution of the family f in equation (3.7) and
logA f (θ ) is the log-ascertainment correction term for the family f in equation (3.8). V̂ar(θˆ ) is
obtained by evaluating Io(θ ) and J(θ ) at the maximum-likelihood estimate θˆ .
The robust variance estimator for the cause-specfic penetrance estimate, Fj(t|θˆ ), is obtained
using Delta method:
Var(Fj(t|θˆ )) = DTθ (t)Var(θˆ )Dθ (t),
whereVar(θˆ ) is the robust variance estimator for θ and Dθ (t) is the vector of partial derivatives
of Fj(t|θˆ ) with respect to θ evaluated at θˆ .
Chapter 4
Simulation
In this chapter, we describe how we simulated family data based on the cause-specific shared
frailty competing risk model with time varying covariates (TVC). We evaluate the performance
of the proposed model under varying degree of familial dependence and three different struc-
tures of TVC in terms of model parameter and penetrance estimation. In Section 4.1, we
summarize objectives of the simulation. In Section 4.2, we describe the data generation pro-
cess. In Section 4.3 we discuss the simulation setting and evaluation criteria for the model
performance. In Section 4.4, we summarize and discuss the simulation results.
4.1 Objectives of the simulation study
The simulation study has three main objectives.
1. To assess the bias and precision of the shared frailty competing risks model under three
different structures (PE, ED, CO) of the time varying covariates.
2. To assess the bias and precision of each PE, ED and CO model under low, medium and
high familial dependence.
3. To assess the bias and precision of each PE, ED and CO model under 1000, 500 and 250
families.
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We designed the simulation study to assess the performance of the model described in Chap-
ter 3 under different scenarios. First, each dataset is generated with two competing events with
PE, ED and CO models, each with low, medium and high familial dependence and the num-
bers of families being 1000, 500, 250. Therefore, we evaluate a total of 3×3×3=27 different
scenarios. For each scenario, the bias and efficiency of the model parameter estimators and
penetrance estimators are evaluated based on 500 simulations and results are summarized in
Section 4.3.
4.2 Data generation
Data were simulated with code modified from the R package ‘FamEvent’ (Choi et al., 2017).
Generation of the cause-specific competing risks survival data is based on the algorithm pro-
posed by Beyersmann et al. (2009). Data generation and analyses were performed using R
version 3.4.3. We choose randomly chosen, different starting seeds to generate data for each
scenario, therefore simulations are completely independent (Burton et al., 2006).
We consider the shared frailty competing risk model with TVC for two competing risks.
For the covariates, we include one TIC and one TVC.
1. G: Binary mutation status TIC. If the individual is a mutation carrier, G takes value of 1
otherwise 0. We assume cause specific hazards for both competing events are affected
by this variable.
2. X(t, ts): Screening status TVC as a function of time t and the screening time ts: X(t, ts) =
I(t ≥ ts). We assume only the cause-specific hazard for event 1 is affected by this vari-
able.
Therefore, the cause-specfic hazards functions for event 1 and event 2 take the following
forms:
h1(t|X(t, ts),G,z1) =h01(t)exp{βg,1G+g(X(t, ts))}z1
h2(t|G,z2) =h02(t)exp{βg,2G}z2, (4.1)
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where h01(t) and h02(t) are the Weibull baseline hazard functions, z1 and z2 are the cause-
specfic shared frailties, βG,1 and βG,2 are the mutation status covariate coefficients for event 1
and 2, respectively, and g(X(t, ts)) is the effect of the screening TVC, X(t, ts), which takes the
following form depending on the model:
g(X(t, ts)) =

0 if t < ts (PE,ED,CO)
βs if t ≥ ts (PE)
βs · exp
{−η(t− ts)} if t ≥ ts (ED)
βs · exp
{−η(t− ts)}+η0 if t ≥ ts (CO) .
The algorithm for generating families takes the following three steps based on model (4.1).
Parameters specified in the data generation process, such as the number of siblings for each
generation in family pedigree and the current age distribution of the probands and other family
members result in the family structure similar to the real data in Chapter 5.
− Step 1: Family structure
(a) For each family, we generate a three-generation pedigree. We fix two members
in the first generation while we generate 2 to 5 siblings in the second and 0 to 2
siblings in the third generations from a truncated negative binomial distribution.
(b) Generate the current age of the proband, a fp from normal distribution with mean
age of 45 and SD of 10. Then we generate the current ages of other family members,
{a f2, ...,a fi} for individual i, i= 2, . . . ,n f , from a normal distribution. The current
ages of the first generation are generated with the mean age equal to a fp +20 with
SD of 1.5 years. The current ages of the second generation are generated from
mean age equivalent to a fp with SD of 1.5 years. Finally, for the third generation,
their current ages are generated with the mean age subtracted by 20 years from the
minimum age of their parents.
(c) To generate the screening TVC, we first generate the screening ages ts for all mem-
bers of the family from a normal distribution with mean age of 40 and variance of
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2 years. If ts, fi > a fi we assume this individual does not experience screening.
(d) Generate shared frailties z f = {z f1,z f2} for family f for two competing events. We
assume z f1 and z f2 are independent and marginally follow the gamma distribution
with shape parameter k1 and the scale parameter 1/k1 for event 1 and k2 and 1/k2
for event 2 respectively.
(e) Generate the mutation status variable G fp for the proband assuming all the probands
are the mutation carriers, based on a dominant model with prespecified BRCA1
mutation allele frequency of 0.0021. Other family members’ mutation statuses are
generated conditioning on the proband’s mutation status from a Bernoulli distribu-
tion with a probability of success equal to P(G fi = 1|G fp). This probability depends
only on the relationship between the proband and the ith member of the family by
Mendelian inheritance laws.
− Step 2: Event times and event types
(a) Generate t fi from the overall survival function: Generate w following a uniform on
[0,1] and solve for t fi from P(Tfi > t fi|G fi, ts, fi,z f ) = w.
(b) Given t fi , we decide the event type δ fi among two competing events using the rate of
the cause-specific hazards at t fi . Compute h1(t fi|G fi, ts, fi,z f ), h2(t fi|G fi, ts, fi,z f ) and
p= h1h1+h2 . Run a Bernoulli experiment with the probability of success p. If success,
then δ fi = 1 otherwise δ fi = 2. If t fi > a fi we regard this individual as censored and
δ fi = 0. Follow-up duration is defined from age 16 to a fi if the individual is right
censored, otherwise it is from age 16 to t fi .
− Step 3: Ascertaiment condition for the family
(a) After generating the event times and types of the family members, keep the family
if it satisfies the condition t fp < a fp . This condition mimics the population based
design of the family studies (Gong and Whittemore, 2003) where probands are
affected before their study entry age, a fp .
(b) Remove men in the pedigree since the real data only consists of women. Mean
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pedigree size of 5 leads to the total number of individuals about 2500 when 500
families are generated, which agrees with BRCA1 data.
To generate the data, we specify the following parameters:
(a) baseline hazard function parameters: λ1 and ρ1 for event 1, λ2 and ρ2 for event 2
(b) parameters involved in TIC: βg,1 and βg,2 as genetic effects for each event
(c) parameters involved in TVC: βs as a screening effect for event 1, η for ED and CO,
additional η0 for CO
(d) familial dependence paramter: k1 and k2 for each event
4.3 Simulation settings and evaluation criteria
Data was generated under the shared frailty competing risks model with three differ-
ent TVCs. Values of the parameters are set using estimates obtained from fitting model
(4.1) to the data described in Chapter 5. Their values and the corresponding penetrance
values are summarized in Table 4.1. We present the true cause-specific penetrances by
age 40, 50, 60 and 70 for Carrier (G=1)/Non-carrier (G=0) and Screened (S=1)/Non-
screened (S=0) subgroups. We generated data with three familial dependences for event
1 (k1 = 7,3.5,1) with n=1000, 500 and 250 families. Low familial dependence structure
is generated with k1 = 7 which corresponds to Kendall’s τ = 0.07. Medium dependence
is generated using k1 = 3.5 so τ = 0.13 and high dependence with k1 = 1 so τ = 0.33.
Kendall’s τ closer to 1 indicates higher dependence between failure times. k2 is fixed
with the estimated value in Table 4.1. We evaluate a total of 9 (3 number of families ×
3 familial dependence levels) scenarios for each TVC model and performed 500 simula-
tions for each scenario.
Model performances are assessed through Bias, Empirical Standard Error (ESE), Aver-
age Standard Error (ASE) and Empirical Coverage Probability (ECP). Table 4.2 summa-
rizes the four criteria for evaluating the performance of the simulation results.
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Table 4.1: Parameter values used for generating family data for our simulation study and the
corresponding penetrance values based on the true parameter values.
Model parameters Cause-specific penetrance given ts = 35
TVC type TVC type TVC type
PE ED CO Event 1 PE ED CO Event 2 PE ED CO
λ1 0.008 0.008 0.008 F1(40;S= 0,G= 0) 0.021 0.024 0.023 F2(40;S= 0,G= 0) 0.005 0.006 0.006
ρ1 2.405 2.300 2.329 F1(40;S= 1,G= 0) 0.028 0.042 0.031 F2(40;S= 1,G= 0) 0.005 0.006 0.006
λ2 0.007 0.007 0.007 F1(40;S= 0,G= 1) 0.133 0.142 0.165 F2(40;S= 0,G= 1) 0.014 0.019 0.027
ρ2 3.080 2.932 2.906 F1(40;S= 1,G= 1) 0.178 0.231 0.210 F2(40;S= 1,G= 1) 0.014 0.018 0.026
βs 0.668 1.872 3.401 F1(50;S= 0,G= 0) 0.045 0.051 0.050 F2(50;S= 0,G= 0) 0.013 0.016 0.016
βg1 1.952 1.858 2.078 F1(50;S= 1,G= 0) 0.075 0.073 0.061 F2(50;S= 1,G= 0) 0.013 0.015 0.016
βg2 1.194 1.224 1.566 F1(50;S= 0,G= 1) 0.265 0.273 0.313 F2(50;S= 0,G= 1) 0.035 0.044 0.062
k1 3.225 3.435 3.536 F1(50;S= 1,G= 1) 0.394 0.359 0.365 F2(50;S= 1,G= 1) 0.032 0.040 0.058
k2 2.900 3.240 3.529 F1(60;S= 0,G= 0) 0.080 0.089 0.086 F2(60;S= 0,G= 0) 0.027 0.031 0.032
η - 0.278 3.530 F1(60;S= 1,G= 0) 0.139 0.109 0.103 F2(60;S= 1,G= 0) 0.026 0.031 0.032
η0 - - 0.160 F1(60;S= 0,G= 1) 0.410 0.413 0.461 F2(60;S= 0,G= 1) 0.065 0.079 0.105
F1(60;S= 1,G= 1) 0.586 0.477 0.514 F2(60;S= 1,G= 1) 0.054 0.070 0.096
F1(70;S= 0,G= 0) 0.124 0.134 0.131 F2(70;S= 0,G= 0) 0.047 0.054 0.055
F1(70;S= 1,G= 0) 0.215 0.153 0.154 F2(70;S= 1,G= 0) 0.045 0.053 0.054
F1(70;S= 0,G= 1) 0.542 0.536 0.581 F2(70;S= 0,G= 1) 0.099 0.116 0.148
F1(70;S= 1,G= 1) 0.721 0.582 0.629 F2(70;S= 1,G= 1) 0.075 0.102 0.132
Bias is the measure of accuracy obtained as the discrepency between the true value of
the parameter, β , and the average parameter estimate over the B simulations performed,
¯ˆβ = ∑Bi βˆi/B. Simulations are designed to mimic the results that could have been ob-
tained from a single study and therefore the uncertainty in the estimate of interest be-
tween simulations, is assessed by the ESE, which is calculated as the standard deviation
of the estimates of interest from all simulations. Acceptable level of bias is considered
to be between 12SE(βˆ ) to 2SE(βˆ ) (Burton et al., 2006). ASE is the average of the robust
standard errors obtained from each simulation. The ESE should be close to the ASE if
the estimates are unbiased (Schafer and Graham, 2002).
Empirical Coverage Probability (ECP) is the proportion of times 95% confidence interval
(CI) defined as βˆi± Z0.975SE(βˆi) include true value β , for i = 1, , ,B, where B is the
number of simulations and βˆi is the estimate of β from simulation i. 95% of the CIs
obtained from simulations have to contain the true parameter value, leading to 5% false
positive rate where we expect 5% of the CIs do not contain true value. Any deviation
from 5% indicates that we expect more or less type I error. For example, ECP higher than
95% results in a loss of statistical power with type I error lower than 5% but too many
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type II error. In contrast, ECP lower than 95% is obtained when more than 5% of the
CIs do not contain the true value. It is more critical since it relates to the increased type
I error, we are rejecting true hypothesis too many times in case of testing the null effect.
Acceptable range of coverage probability can be computed from the nominal coverage
probability (p) and the number of independent simulations (B), as p± 2SE(p) where
SE(p) =
√
p(1− p)/B (Tang et al., 2005). For our simulation, we have SE(p) = 0.0097
leading to the acceptable range of ECP between 93.05% and 96.95% for the nominal
95% coverage probability (p= 0.95).
Table 4.2: Summary of evaluation criteria.
Evaluation criteria Formula
Bias ¯ˆβ -β
Difference between the
average estimate and the true value.
Empirical Standard Error (ESE)
√
[1/(B−1)]∑Bi=1(βˆi− ¯ˆβ )2
Standard deviation of the estimates
of interest from all simulations.
Average Standard Error (ASE) ∑Bi=1 SE(βˆi)/B
Average of robust SEs from
each simulation i, i= 1, ...,B.
Empirical Coverage Probability (ECP) Proportion of times 95% confidence interval defined as
βˆi±Z0.975SE(βˆi) include true value β , for i= 1, ,B.
B is the number of simulations, β is the true value of the parameter, βˆi is the estimate of β from simulation i,
¯ˆβ is average of the parameter estimates across all the simulations,
SE(βˆi) is the estimated robust standard error from simulation i.
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4.4 Simulation results and discussions
Simulation results of 500 families settings are summarized in Tables 4.3 to 4.5. Results
of 1000 and 250 families are presented in the Tables A.1 to A.6 in the Appendix A. In
Figures 4.1 to 4.6, we visualize the results for all the scenarios considered. Boxplots
of the model parameters estimates are presented in Figures A.1 to A.6. We compare
the bias in the model parameters and penetrance estimations between frailty model and
independent model assuming data is generated with familial clustering in Table A.7 to
A.10.
4.4.1 Cause-specific penetrances
Table 4.3 represents the result from PE TVC model including bias, ESE, ASE and ECP
of the model parameters and cause-specific penetrance estimates for event 1 and 2. Table
4.4 and 4.5 summarize the results from ED and CO models, respectively. All the TVC
models work well in terms of penetrance bias and precision for the event 1 and 2; bias
was negligible (< 1%) and ECPs were on average close to the 0.95 nominal level, ranged
between 0.93 and 0.97 regardless of familial dependence levels. ASE and ESE mostly
agreed in PE and ED models but ESE tends to be higher than ASE in the CO model.
In addition, for the penetrance by age 70 for mutation carrier and screened individuals,
ASEs were higher than ESEs indicating confidence intervals are slightly conservative
leading to ECPs higher than nominal 95%. Figures 4.1 to 4.3 visualize accuracy and
precision of the penetrance estimates for mutation carriers from n = 1000, 500 and 250
families based on 500 simulations for each TVC model. Solid red lines are the true pen-
etrances for the the screened given that the screening occurred at age 35. Solid blue lines
are those of the non-screened. Four small circles on each solid line indicate the mean
penetrance estimates at age 40, 50, 60 and 70 respectively, while error bars are mean
penetrance estimates± 1.96ASE. Close alignments of solid lines and the circles indicate
models produced negligible biases. We note that the true penetrance decreases with in-
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creasing familial dependence ceteris paribus. There was approximately 10% difference
in penetrance by age 70 for the screened carrier between medium and high familial de-
pendence across all the TVC models. For the PE model, difference in the penetrances
by age 70 between screened and non-screened groups was larger (19% in low, 18% in
medium and 13% in high familial dependence) than ED and CO models (5% in low and
medium, 3% in high familial dependence).
Generally, we observe accuracy of the penetrance estimates decreases with smaller num-
ber of families comparing the bias from Tables 4.3 to 4.6 to Tables A.1 to A.6, however
bias is negligible regardless of the number of families. Figures 4.1 to 4.3 show that ver-
tical lengths of the error bars increase as we reduce the number of families from 1000 to
250 indicating the precision of penetrance estimation also decreases with smaller num-
ber of families. Condifence intervals for the screened are slightly larger than the non-
screened when evaluated at the ages 40, 50, 60 and 70. Cause-specific penetrance for
event 2 is much smaller than the event 1 in our simulation settings (10% vs 65% by age
70).
In PE models from Tables 4.3, high familial dependence results in the smaller penetrance
bias compared to the medium and low familial dependence (0.06% vs 0.17% at age 70
for event 1). In CO models from Table 4.6, however high familial dependence leads to
the largest bias (0.13% vs 0.07% at age 70 for event 1). In PE model, ECPs for the
event 2 are slightly lower in the low familial dependence (92% in low vs 93% in medium
vs 93% in high for the lowest ECP acquired) but ED and CO models do not exhibit
this pattern. In 500 and 250 families settings, penetrance biases are the highest in high
familial dependence across all TVC models.
4.4.2 Model parameters
The model parameter estimates are presented in upper rows of Tables 4.3 to 4.5. ASEs
and ESEs for all the parameter estimates agree each other and ECPs are mostly within ac-
36 CHAPTER 4. SIMULATION
ceptable range between 0.93 and 0.97 except for the frailty parameters (ranged between
0.86 and 0.97). ASEs tend to be larger than ESE in CO model. Lowest ECP occurred in
PE model for k2 and generally it has worse coverage than k1. Again, bias is negligible
for all the parameters except for the frailty parameters. Figures 4.4 and 4.5 visualize the
results for the screening effect parameter, βs and mutation gene effect for event 1, βg,1.
Results for the mutation gene effect for event 2, βg,1, are presented in Table A.7. Figures
compare the bias and the confidence intervals for PE, ED and CO models across all the
number of families and familial dependence. All the TVC models work relatively well in
terms of bias and precision for βs with 1000 families regardless of familial dependence
levels. However, CO model tends to overestimate βs with 250 families when familial
dependence is low or high. βg,1 estimates are unbiased regardless the TVC models and
the number of families but βg,2 estimates were slightly overestimated in 250 families.
Precision and accuracy of frailty parameter estimates are relatively poorer compared to
the other parameters in the model. Figure 4.6 summarizes the simulation results for
frailty paramter k1. ASE increases substantially with the lower familial dependence
across all TVC models. This pattern is especially prominent in PE model.
We had some convergence issues under CO model; about 2% and 6% of the total simula-
tions did not converge, respectively, with 500 families and 250 families. Each simulation
is successfully completed only if optim function returned convergence code 0. Those
with error code 10, implying degeneracy of the Nelder-Mead simplex, were discarded
and additional data was generated to achieve 500 replications. PE and ED model had no
convergence issues across all the sample sizes and dependence levels. CO model with
1000 families had no convergence issue but in 500 families setting, the simulations did
not converge about 1.9% (28/1500) of total simulations. In 250 families setting, those
numbers increase to about 5.9% (89/1500). Generally, CO model is susceptible to bias
when the number of families are lower.
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Table 4.3: (500 families) Empirical properties of the parameter and penetrance estimators
for shared frailty competing risks model with Permanent Exposure TVC under low (k1 = 7),
medium (k1 = 3.5) and high (k1 = 1) familial dependence of the event times for event 1 based
on 500 simulations.
Permanent Exposure Model
True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
log(λ1) -4.83 -0.01 0.06 0.06 0.95 -4.83 0.00 0.06 0.06 0.95 -4.83 0.00 0.06 0.06 0.94
log(ρ1) 0.88 0.00 0.03 0.03 0.94 0.88 0.00 0.03 0.03 0.93 0.88 0.00 0.03 0.03 0.96
log(λ2) -4.96 -0.01 0.09 0.10 0.95 -4.96 -0.02 0.10 0.10 0.94 -4.96 -0.01 0.09 0.10 0.96
log(ρ2) 1.12 0.00 0.07 0.07 0.95 1.12 0.00 0.07 0.07 0.95 1.12 0.00 0.06 0.07 0.96
βs 0.67 0.01 0.11 0.11 0.95 0.67 0.00 0.10 0.11 0.96 0.67 0.00 0.11 0.11 0.96
βg1 1.95 0.01 0.12 0.12 0.95 1.95 0.01 0.12 0.12 0.96 1.95 0.00 0.12 0.11 0.94
βg2 1.19 0.03 0.23 0.23 0.96 1.19 0.03 0.24 0.23 0.95 1.19 0.02 0.22 0.24 0.96
log(k1) 1.95 0.24 1.08 0.85 0.92 1.25 0.13 0.69 0.48 0.95 0.00 0.02 0.25 0.25 0.95
log(k2) 1.06 0.62 2.17 1.38 0.80 1.06 0.72 2.20 1.41 0.84 1.06 0.61 2.05 1.46 0.86
Cause-specific penetrance (%) given tsc = 35
Event 1
F1(40;S= 0,G= 0) 2.06 -0.01 0.26 0.26 0.93 2.05 0.00 0.26 0.27 0.94 2.04 0.01 0.29 0.28 0.95
F1(40;S= 1,G= 0) 2.85 0.00 0.35 0.35 0.95 2.84 0.00 0.36 0.36 0.94 2.81 0.02 0.39 0.39 0.94
F1(40;S= 0,G= 1) 13.43 -0.06 1.06 1.06 0.95 13.31 0.02 1.14 1.12 0.96 12.72 -0.02 1.30 1.30 0.95
F1(40;S= 1,G= 1) 18.06 0.02 1.42 1.46 0.95 17.83 0.05 1.59 1.53 0.94 16.80 -0.01 1.71 1.75 0.95
F1(50;S= 0,G= 0) 4.53 -0.04 0.53 0.52 0.94 4.52 0.00 0.52 0.54 0.95 4.45 0.03 0.59 0.58 0.94
F1(50;S= 1,G= 0) 7.56 0.00 0.91 0.92 0.95 7.52 0.00 0.91 0.94 0.95 7.32 0.05 0.99 0.99 0.95
F1(50;S= 0,G= 1) 27.07 -0.14 1.84 1.83 0.95 26.56 0.06 1.97 1.97 0.96 24.38 -0.03 2.28 2.30 0.94
F1(50;S= 1,G= 1) 40.70 0.03 3.04 3.08 0.96 39.60 0.09 3.24 3.20 0.95 35.11 0.00 3.33 3.47 0.95
F1(60;S= 0,G= 0) 8.07 -0.07 0.91 0.89 0.94 8.02 0.00 0.88 0.92 0.94 7.80 0.05 1.00 0.97 0.94
F1(60;S= 1,G= 0) 14.05 0.00 1.63 1.64 0.94 13.91 0.01 1.61 1.67 0.95 13.26 0.09 1.72 1.73 0.96
F1(60;S= 0,G= 1) 42.42 -0.24 2.62 2.62 0.95 41.23 0.10 2.79 2.81 0.95 36.41 -0.02 3.19 3.25 0.94
F1(60;S= 1,G= 1) 61.28 -0.09 3.85 3.86 0.95 58.99 0.09 4.07 4.06 0.95 50.29 -0.01 4.27 4.45 0.95
F1(70;S= 0,G= 0) 12.56 -0.10 1.38 1.36 0.95 12.45 0.01 1.33 1.40 0.94 11.93 0.07 1.48 1.45 0.94
F1(70;S= 1,G= 0) 21.92 -0.01 2.45 2.45 0.94 21.58 0.02 2.37 2.48 0.95 20.09 0.13 2.49 2.50 0.96
F1(70;S= 0,G= 1) 56.52 -0.33 3.20 3.18 0.94 54.51 0.12 3.39 3.42 0.94 46.80 -0.02 3.84 3.92 0.95
F1(70;S= 1,G= 1) 75.63 -0.23 3.75 3.74 0.94 72.59 0.03 4.08 4.06 0.94 61.08 -0.04 4.61 4.79 0.94
Event 2
F2(40;S= 0,G= 0) 0.46 -0.01 0.10 0.11 0.92 0.46 -0.01 0.11 0.11 0.94 0.46 -0.01 0.10 0.11 0.93
F2(40;S= 1,G= 0) 0.46 -0.01 0.10 0.10 0.92 0.46 -0.01 0.11 0.11 0.94 0.46 -0.01 0.10 0.10 0.93
F2(40;S= 0,G= 1) 1.40 0.01 0.22 0.22 0.94 1.41 0.00 0.21 0.22 0.95 1.41 -0.01 0.23 0.22 0.94
F2(40;S= 1,G= 1) 1.38 0.00 0.21 0.21 0.93 1.38 0.00 0.20 0.21 0.94 1.39 -0.01 0.22 0.22 0.94
F2(50;S= 0,G= 0) 1.27 -0.02 0.24 0.25 0.93 1.27 -0.02 0.25 0.25 0.93 1.27 -0.02 0.23 0.25 0.94
F2(50;S= 1,G= 0) 1.25 -0.02 0.24 0.24 0.93 1.25 -0.02 0.25 0.24 0.93 1.25 -0.02 0.23 0.24 0.94
F2(50;S= 0,G= 1) 3.53 0.01 0.42 0.42 0.94 3.54 -0.01 0.41 0.42 0.94 3.58 -0.01 0.47 0.45 0.93
F2(50;S= 1,G= 1) 3.21 0.00 0.39 0.38 0.93 3.23 -0.01 0.37 0.39 0.94 3.31 -0.01 0.42 0.40 0.94
F2(60;S= 0,G= 0) 2.67 -0.05 0.47 0.48 0.94 2.67 -0.05 0.49 0.48 0.93 2.67 -0.03 0.45 0.49 0.95
F2(60;S= 1,G= 0) 2.57 -0.05 0.45 0.46 0.94 2.57 -0.05 0.48 0.47 0.93 2.58 -0.03 0.44 0.48 0.95
F2(60;S= 0,G= 1) 6.48 0.02 0.74 0.73 0.95 6.53 -0.02 0.73 0.74 0.94 6.74 0.00 0.82 0.79 0.94
F2(60;S= 1,G= 1) 5.32 0.00 0.62 0.61 0.93 5.42 -0.02 0.61 0.62 0.94 5.83 -0.01 0.69 0.67 0.94
F2(70;S= 0,G= 0) 4.73 -0.08 0.82 0.85 0.94 4.73 -0.08 0.87 0.85 0.93 4.74 -0.05 0.79 0.88 0.95
F2(70;S= 1,G= 0) 4.45 -0.08 0.77 0.80 0.94 4.45 -0.08 0.82 0.80 0.93 4.49 -0.05 0.75 0.83 0.95
F2(70;S= 0,G= 1) 9.68 0.04 1.16 1.15 0.94 9.85 -0.04 1.16 1.18 0.95 10.52 0.02 1.29 1.28 0.95
F2(70;S= 1,G= 1) 7.12 0.01 0.91 0.89 0.94 7.42 -0.04 0.91 0.92 0.95 8.56 0.00 1.04 1.04 0.95
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Table 4.4: (500 families) Empirical properties of the parameter and penetrance estimators for
shared frailty competing risks model with Exponential Decay TVC under low (k1 = 7), medium
(k1 = 3.5) and high (k1 = 1) familial dependence of the event times for event 1 based on 500
simulations.
Exponential Decay Model
True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
log(λ1) -4.83 -0.01 0.05 0.06 0.96 -4.83 0.00 0.06 0.06 0.95 -4.83 0.00 0.06 0.06 0.96
log(ρ1) 0.83 0.00 0.03 0.03 0.96 0.83 0.00 0.03 0.03 0.95 0.83 0.00 0.03 0.03 0.96
log(λ2) -4.96 0.00 0.09 0.09 0.95 -4.96 -0.01 0.09 0.09 0.96 -4.96 -0.01 0.09 0.09 0.95
log(ρ2) 1.08 0.00 0.06 0.06 0.95 1.08 0.00 0.06 0.06 0.95 1.08 0.00 0.06 0.06 0.95
βs 1.87 0.03 0.25 0.25 0.94 1.87 -0.01 0.25 0.25 0.95 1.87 0.03 0.24 0.24 0.94
βg1 1.86 0.00 0.12 0.12 0.96 1.86 0.01 0.11 0.12 0.95 1.86 0.01 0.11 0.11 0.94
βg2 1.22 0.01 0.20 0.21 0.95 1.22 0.03 0.22 0.21 0.96 1.22 0.02 0.21 0.22 0.96
log(k1) 1.95 0.23 0.99 0.88 0.93 1.25 0.08 0.49 0.48 0.97 0.00 0.02 0.23 0.24 0.96
log(k2) 1.18 0.51 2.04 1.18 0.85 1.18 0.53 1.70 1.26 0.84 1.18 0.48 1.47 1.28 0.84
log(η) -1.28 0.02 0.32 0.31 0.94 -1.28 0.00 0.32 0.31 0.94 -1.28 0.03 0.30 0.30 0.94
Cause-specific penetrance (%) given tsc = 35
Event 1
F1(40;S= 0,G= 0) 2.43 0.00 0.29 0.30 0.95 2.42 0.00 0.30 0.30 0.95 2.40 -0.01 0.32 0.31 0.93
F1(40;S= 1,G= 0) 4.21 0.01 0.59 0.59 0.95 4.20 -0.02 0.59 0.59 0.93 4.14 -0.02 0.57 0.60 0.95
F1(40;S= 0,G= 1) 14.36 -0.05 1.01 1.10 0.96 14.21 0.04 1.14 1.16 0.95 13.55 0.02 1.29 1.32 0.97
F1(40;S= 1,G= 1) 23.47 -0.03 2.16 2.28 0.95 23.09 -0.08 2.26 2.30 0.95 21.41 0.03 2.25 2.37 0.95
F1(50;S= 0,G= 0) 5.16 -0.01 0.57 0.58 0.94 5.14 0.00 0.58 0.59 0.94 5.04 -0.02 0.62 0.62 0.94
F1(50;S= 1,G= 0) 7.30 0.04 0.95 0.94 0.94 7.26 0.03 0.94 0.95 0.95 7.08 -0.01 0.90 0.96 0.96
F1(50;S= 0,G= 1) 27.84 -0.13 1.66 1.84 0.97 27.30 0.03 1.87 1.96 0.96 25.01 0.05 2.19 2.25 0.95
F1(50;S= 1,G= 1) 36.87 0.04 2.84 3.04 0.96 35.95 0.12 2.99 3.09 0.95 32.16 0.13 2.93 3.18 0.97
F1(60;S= 0,G= 0) 8.91 -0.03 0.94 0.96 0.94 8.85 -0.01 0.95 0.97 0.94 8.59 -0.03 1.01 1.01 0.94
F1(60;S= 1,G= 0) 10.98 0.05 1.26 1.26 0.94 10.89 0.05 1.24 1.27 0.94 10.49 0.00 1.23 1.28 0.97
F1(60;S= 0,G= 1) 42.49 -0.21 2.26 2.56 0.97 41.29 0.00 2.55 2.73 0.97 36.44 0.10 3.00 3.09 0.95
F1(60;S= 1,G= 1) 49.34 0.00 2.94 3.22 0.97 47.76 0.16 3.16 3.36 0.97 41.55 0.20 3.33 3.61 0.96
F1(70;S= 0,G= 0) 13.55 -0.05 1.39 1.42 0.94 13.42 -0.02 1.41 1.44 0.94 12.82 -0.04 1.47 1.47 0.94
F1(70;S= 1,G= 0) 15.49 0.03 1.64 1.64 0.94 15.32 0.05 1.62 1.66 0.94 14.54 0.00 1.61 1.68 0.97
F1(70;S= 0,G= 1) 55.65 -0.28 2.70 3.07 0.97 53.68 -0.05 3.03 3.27 0.96 46.14 0.12 3.56 3.68 0.96
F1(70;S= 1,G= 1) 60.49 -0.10 2.99 3.33 0.97 58.24 0.10 3.26 3.54 0.97 49.69 0.21 3.67 3.94 0.96
Event 2
F2(40;S= 0,G= 0) 0.59 0.00 0.12 0.12 0.93 0.59 -0.01 0.12 0.12 0.93 0.59 0.00 0.12 0.12 0.95
F2(40;S= 1,G= 0) 0.59 0.00 0.12 0.12 0.93 0.59 -0.01 0.12 0.12 0.93 0.59 0.00 0.12 0.12 0.95
F2(40;S= 0,G= 1) 1.86 0.00 0.26 0.26 0.95 1.86 0.00 0.27 0.26 0.94 1.86 0.01 0.26 0.26 0.97
F2(40;S= 1,G= 1) 1.78 0.00 0.25 0.24 0.95 1.78 0.00 0.25 0.25 0.93 1.80 0.00 0.24 0.25 0.97
F2(50;S= 0,G= 0) 1.55 0.00 0.27 0.28 0.94 1.55 -0.02 0.27 0.28 0.93 1.56 -0.01 0.26 0.28 0.96
F2(50;S= 1,G= 0) 1.52 0.00 0.27 0.27 0.94 1.53 -0.02 0.27 0.27 0.94 1.53 -0.01 0.26 0.28 0.96
F2(50;S= 0,G= 1) 4.42 0.01 0.47 0.48 0.95 4.44 0.01 0.51 0.49 0.94 4.49 0.00 0.50 0.51 0.96
F2(50;S= 1,G= 1) 3.99 0.00 0.42 0.43 0.95 4.02 0.00 0.45 0.44 0.94 4.12 -0.01 0.44 0.46 0.96
F2(60;S= 0,G= 0) 3.14 0.00 0.52 0.53 0.94 3.14 -0.05 0.51 0.53 0.94 3.14 -0.03 0.50 0.54 0.96
F2(60;S= 1,G= 0) 3.07 0.00 0.51 0.52 0.94 3.07 -0.05 0.50 0.52 0.94 3.07 -0.03 0.48 0.53 0.96
F2(60;S= 0,G= 1) 7.81 0.03 0.78 0.81 0.96 7.87 0.02 0.86 0.82 0.93 8.13 -0.02 0.86 0.87 0.96
F2(60;S= 1,G= 1) 6.90 0.00 0.69 0.71 0.96 6.99 0.00 0.74 0.72 0.95 7.38 -0.03 0.75 0.77 0.96
F2(70;S= 0,G= 0) 5.39 0.01 0.90 0.91 0.95 5.39 -0.07 0.86 0.92 0.95 5.41 -0.05 0.85 0.93 0.96
F2(70;S= 1,G= 0) 5.26 0.01 0.87 0.89 0.95 5.26 -0.07 0.83 0.89 0.95 5.28 -0.06 0.83 0.91 0.95
F2(70;S= 0,G= 1) 11.38 0.05 1.18 1.22 0.96 11.57 0.04 1.29 1.24 0.95 12.34 -0.05 1.34 1.35 0.95
F2(70;S= 1,G= 1) 9.97 0.01 1.05 1.09 0.96 10.22 0.01 1.12 1.12 0.95 11.20 -0.07 1.20 1.22 0.95
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Table 4.5: (500 families) Empirical properties of the parameter and penetrance estimators for
shared frailty competing risks model with Cox and Oakes TVC under low (k1 = 7), medium
(k1 = 3.5) and high (k1 = 1) familial dependence of the event times for event 1 based on 500
simulations.
Cox and Oakes Model
True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
log(λ1) -4.83 0.00 0.05 0.06 0.95 -4.83 0.00 0.05 0.06 0.94 -4.83 0.00 0.05 0.06 0.96
log(ρ1) 0.83 0.00 0.03 0.03 0.94 0.83 0.00 0.03 0.03 0.96 0.83 0.00 0.03 0.03 0.97
log(λ2) -4.96 0.00 0.07 0.09 0.95 -4.96 0.00 0.07 0.09 0.97 -4.96 0.00 0.08 0.09 0.95
log(ρ2) 1.07 0.00 0.05 0.06 0.96 1.07 0.00 0.05 0.06 0.97 1.07 0.00 0.05 0.06 0.96
βs 1.52 0.04 0.32 0.42 0.96 1.52 0.04 0.33 0.42 0.94 1.52 0.02 0.32 0.42 0.96
βg1 2.08 0.01 0.10 0.12 0.94 2.08 0.01 0.10 0.12 0.95 2.08 0.01 0.09 0.11 0.96
βg2 1.57 0.00 0.17 0.21 0.98 1.57 0.00 0.17 0.21 0.94 1.57 0.01 0.16 0.21 0.97
log(k1) 1.95 0.20 0.74 0.86 0.91 1.25 0.10 0.39 0.46 0.96 0.00 0.02 0.18 0.22 0.97
log(k2) 1.26 0.38 1.15 1.39 0.86 1.26 0.35 0.98 1.40 0.90 1.26 0.36 1.10 1.32 0.87
log(η) -0.18 -0.02 0.50 0.58 0.90 -0.18 0.01 0.50 0.60 0.91 -0.18 -0.03 0.48 0.62 0.91
η0 0.21 -0.02 0.12 0.14 0.95 0.21 -0.01 0.12 0.14 0.96 0.21 -0.02 0.12 0.14 0.95
Cause-specific penetrance (%) given tsc = 35
Event 1
F1(40;S= 0,G= 0) 2.43 0.01 0.28 0.29 0.95 2.42 0.00 0.29 0.30 0.94 2.40 0.00 0.28 0.30 0.95
F1(40;S= 1,G= 0) 3.25 0.05 0.44 0.45 0.95 3.24 0.03 0.44 0.45 0.94 3.21 0.03 0.43 0.46 0.96
F1(40;S= 0,G= 1) 17.45 0.09 1.24 1.21 0.95 17.23 0.09 1.25 1.26 0.94 16.27 0.08 1.40 1.43 0.95
F1(40;S= 1,G= 1) 22.47 0.32 2.08 2.03 0.93 22.12 0.21 1.95 2.05 0.97 20.56 0.23 2.01 2.13 0.96
F1(50;S= 0,G= 0) 5.15 0.01 0.54 0.58 0.95 5.13 0.01 0.58 0.58 0.94 5.04 0.02 0.56 0.60 0.96
F1(50;S= 1,G= 0) 6.57 0.07 0.82 0.83 0.95 6.54 0.04 0.83 0.83 0.94 6.39 0.04 0.80 0.84 0.95
F1(50;S= 0,G= 1) 32.90 0.12 1.97 1.95 0.96 32.16 0.16 2.09 2.05 0.94 29.06 0.19 2.27 2.34 0.96
F1(50;S= 1,G= 1) 39.48 0.33 3.15 2.92 0.93 38.43 0.29 2.89 2.97 0.96 34.14 0.26 2.95 3.06 0.95
F1(60;S= 0,G= 0) 8.91 0.02 0.90 0.96 0.96 8.85 0.01 0.97 0.96 0.95 8.58 0.04 0.92 0.98 0.96
F1(60;S= 1,G= 0) 11.09 0.03 1.36 1.37 0.95 11.00 0.01 1.37 1.37 0.94 10.59 0.01 1.32 1.37 0.95
F1(60;S= 0,G= 1) 48.48 0.11 2.59 2.59 0.95 46.94 0.23 2.79 2.73 0.94 40.89 0.28 2.94 3.07 0.96
F1(60;S= 1,G= 1) 55.53 0.07 3.86 3.61 0.93 53.57 0.17 3.63 3.69 0.95 46.03 0.16 3.66 3.78 0.96
F1(70;S= 0,G= 0) 13.54 0.02 1.36 1.42 0.95 13.41 0.02 1.44 1.43 0.95 12.81 0.08 1.34 1.43 0.96
F1(70;S= 1,G= 0) 16.60 -0.04 2.00 2.03 0.95 16.41 -0.04 2.02 2.03 0.94 15.52 -0.02 1.89 1.99 0.95
F1(70;S= 0,G= 1) 61.12 0.07 2.90 2.93 0.96 58.82 0.25 3.15 3.10 0.94 50.11 0.32 3.32 3.49 0.97
F1(70;S= 1,G= 1) 67.55 -0.15 3.94 3.73 0.93 64.90 0.06 3.80 3.86 0.95 54.88 0.09 3.94 4.09 0.95
Event 2
F2(40;S= 0,G= 0) 0.62 0.01 0.12 0.13 0.96 0.62 0.01 0.12 0.13 0.95 0.62 -0.01 0.11 0.13 0.97
F2(40;S= 1,G= 0) 0.62 0.01 0.12 0.13 0.96 0.62 0.01 0.12 0.13 0.95 0.62 -0.01 0.11 0.13 0.97
F2(40;S= 0,G= 1) 2.66 0.00 0.31 0.33 0.96 2.67 0.00 0.32 0.33 0.96 2.68 -0.01 0.33 0.34 0.94
F2(40;S= 1,G= 1) 2.58 0.00 0.30 0.32 0.96 2.59 0.00 0.31 0.32 0.96 2.61 -0.01 0.32 0.33 0.95
F2(50;S= 0,G= 0) 1.61 0.01 0.27 0.29 0.95 1.61 0.01 0.27 0.29 0.95 1.61 -0.01 0.26 0.29 0.95
F2(50;S= 1,G= 0) 1.59 0.01 0.27 0.28 0.95 1.59 0.01 0.27 0.28 0.95 1.59 -0.01 0.26 0.28 0.95
F2(50;S= 0,G= 1) 6.11 -0.02 0.56 0.59 0.96 6.13 0.00 0.60 0.60 0.96 6.24 -0.03 0.62 0.63 0.95
F2(50;S= 1,G= 1) 5.66 -0.03 0.52 0.54 0.96 5.70 -0.01 0.55 0.55 0.96 5.86 -0.04 0.58 0.58 0.95
F2(60;S= 0,G= 0) 3.23 0.02 0.51 0.54 0.94 3.23 0.02 0.52 0.55 0.95 3.24 -0.02 0.51 0.55 0.95
F2(60;S= 1,G= 0) 3.18 0.02 0.50 0.53 0.95 3.18 0.02 0.51 0.54 0.96 3.18 -0.02 0.50 0.54 0.96
F2(60;S= 0,G= 1) 10.30 -0.03 0.88 0.95 0.97 10.42 0.00 0.97 0.96 0.95 10.90 -0.05 1.02 1.03 0.95
F2(60;S= 1,G= 1) 9.22 -0.06 0.83 0.87 0.94 9.37 -0.02 0.89 0.89 0.96 10.00 -0.06 0.93 0.94 0.95
F2(70;S= 0,G= 0) 5.53 0.04 0.87 0.93 0.95 5.53 0.05 0.88 0.93 0.95 5.55 -0.02 0.89 0.95 0.95
F2(70;S= 1,G= 0) 5.39 0.03 0.85 0.90 0.95 5.39 0.04 0.85 0.91 0.95 5.42 -0.02 0.87 0.93 0.95
F2(70;S= 0,G= 1) 14.27 -0.06 1.24 1.37 0.98 14.61 -0.02 1.38 1.41 0.94 15.91 -0.08 1.51 1.55 0.95
F2(70;S= 1,G= 1) 12.35 -0.06 1.22 1.28 0.96 12.77 -0.02 1.31 1.32 0.95 14.36 -0.07 1.41 1.45 0.95
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Figure 4.1: Accuracy and precision of the penetrance estimates for mutation carriers from n
= 1000 families based on 500 simulations. The red line represents the true penetrance of the
screened group and the blue line represents non-screened group.
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Figure 4.2: Accuracy and precision of the penetrance estimates for mutation carriers from n
= 500 families based on 500 simulations. The red line represents the true penetrance of the
screened group and the blue line represents non-screened group.
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Figure 4.3: Accuracy and precision of the penetrance estimates for mutation carriers from n
= 250 families based on 500 simulations. The red line represents the true penetrance of the
screened group and the blue line represents non-screened group.
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Figure 4.4: Bias and precision of the parameter estimates for screen effect, βs, expressed as
bias ± 1.96ASE, based on 500 simulations. True value of the βs is 0.668 for PE, 1.872 for ED
and 3.401 for CO.
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Figure 4.5: Bias and precision of the parameter estimates for mutation effect for event 1, βg,1,
expressed as bias± 1.96ASE, based on 500 simulations. True value of the βg,1 is 1.952 for PE,
1.858 for ED and 2.078 for CO.
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Figure 4.6: Bias and precision of the parameter estimates for frailty parameter for event 1, k1,
expressed as bias ± 1.96ASE, based on 500 simulations. True value of the log(k1) is 2.30 for
low, 1.25 for medium and 0 for high familial dependence.
Chapter 5
Application to hereditary breast and
ovarian cancer families
This chapter presents the analysis of the BRCA1/2 mutation positive family data. Sec-
tion 5.1 introduces the data and descriptive statistics. Then in Section 5.2, we describe
the specification of the model fitted. Fianlly in Section 5.3, we summarize and discuss
the modelling results. Our main focus is on the relative risk estimation of woman who
undergoes Bilateral Oophorectomy (BO) and Mammographic Screenings (MS) and the
cause-specific penetrance estimation of the event of interest which is breast cancer, ac-
counting for the competing risks, familial dependence and the ascertainment bias. Com-
parison of the models with different TVC functions is also presented. We used custom
codes based on FamEvent R package to fit the model. Some of the key R functions are
listed in Appendix B.
5.1 The data
Our study data consists of 876 BRCA positive families recruited through the Breast Can-
cer Family Registries (BCFRs). The BCFRs database (John et al., 2004) was established
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in 1995 with six participating sites from USA, Austrailia and Canada including Ontario
Cancer Care. BCFRs enrolled most of the families from 1996 to 2000 while continu-
ing to recruit additional families satisfying its criteria. Families are registered if BRCA1
or BRCA2 mutations pass down to further generations (segregating mutation), exhibit
multiple cases of breast or ovarian cancer, have Ashkenazi Jewish ancestry or come from
specific racial and ethnic groups. For the population based families, each family includes
the proband, i.e. the initial member of the family to come under study, as well as the first
and the second degree relatives. Data have extensive information on the family members
including the ages at breast/ovarian cancer diagnosis, study entry, screenings including
Magnetic Resonance Imaging (MRI) and mammography and surgeries (Mastectomy and
Oophorectomy) and mutation status in BRCA1/2 gene. The data consist of 4575 women
including 498 BRCA1 families (2650 women) and 378 BRCA2 families (1925 women).
Among 4575 women, 1639 women develop breast cancer (BC) as the first event. Breast
cancer is the event of interest and the ovarian cancer (OC) and the death are considered
as the competing events. Women are right censored if they do not experience any of the
endpoints during follow-up. Figure 5.1 summarizes the data we have for analysis.
Figure 5.1: Total number of women entered the study with competing risks, BRCA1/2 com-
bined.
We separately analyzed the BRCA1 mutation positive families and the BRCA2 mutation
positive families. Detailed descriptive statistics of the BRCA1 and the BRCA2 families
are presented in Tables 5.1 and 5.2. We only considered those screenings and surgeries
which occured before any events (cancers or death). The proportion of the women who
have OC as the first cancer is much lower than that of BC in both BRCA1/2. (34.9% vs
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6.9% in BRCA1, 37.1% vs 3.2% in BRCA2). We include two surgeries into the analysis:
Bilateral Mastectomy (BM) and Bilateral Oophorectomy (BO). If the woman has BM,
She cannot develop breast cancer after the surgery since breast tissue is missing while BO
similarly prevents ovarian cancer. This is reflected in the data as the breast cancer cohort
has no BM and ovarian cancer cohort has no BO in Tables 5.1 and 5.2. Also, we still
have very limited number of women who undergo BO among the breast cancer cohort
(4.3% in BRCA1, 4.5% in BRCA2) and BM among the ovarian cancer cohort (0.6% in
BRCA1, 0% in BRCA2). The former case is of more interest concerning the evidence
of the negative association between the oophorectomy and the etiology of breast cancer
(Eisen et al., 2005).
Table 5.1: Descriptive statistics of BRCA1 positive families.
Breast Cancer Ovarian Cancer Death Censored Total
N (%) 924 (34.9%) 182 (6.9%) 958 (36.2%) 586 (22.1%) 2650
Event age
mean (SD) 44.2 (12.0) 53.0 (11.5) 70.5 (17.9) 50.9 (16.2) 55.8 (19.1)
min, max 21.0, 86.0 28.0, 89.0 18.5, 102.5 18.1, 95.0 18.1, 102.5
BRCA Mutation
Noncarrier 29 (3.1%) 4 (2.2%) 14 (1.5%) 229 (39.1%) 276 (10.4%)
Carrier 483 (52.3%) 55 (30.2%) 16 (1.7%) 192 (32.8%) 746 (28.2%)
Untested 412 (44.6%) 123 (67.6%) 928 (96.9%) 165 (28.2%) 1628 (61.4%)
# of screening
0 722 (78.1%) 158 (86.8%) 944 (98.5%) 257 (43.9%) 2081 (78.5%)
1 157 (17.0%) 19 (10.4%) 7 (0.7%) 174 (29.7%) 357 (13.5%)
2 30 (3.3%) 4 (2.2%) 3 (0.3%) 58 (10.0%) 95 (3.6%)
3+ 15 (1.6%) 1 (0.6%) 4 (0.4%) 97 (16.6%) 117 (4.4%)
Surgery
None 884 (95.7%) 181 (99.5%) 946 (98.8%) 441 (75.3%) 2452 (92.5%)
BM 0 (0.0%) 1 (0.6%) 3 (0.3%) 16 (2.7%) 20 (0.8%)
BO 40 (4.3%) 0 (0.0%) 9 (0.9%) 85 (14.5%) 134 (5.1%)
Both 0 (0.0%) 0 (0.0%) 0 (0.0%) 44 (7.5%) 44 (1.7%)
BO for Bilateral Oophorectomy, BM for Bilateral Mastectomy and SD for Standard Deviation.
Most women were not screened (78.5% in BRCA1, 76.8% in BRCA2). If they were
screened, they commonly have just one screening (13.5% in BRCA1, 13.7% in BRCA2).
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A small proportion of women had multiple screens (8% in BRCA1, 9.5% in BRCA2) and
most women who have multiple screenings have not yet developed any cancer or died.
Table 5.2: Descriptive statistics of BRCA2 mutation positive analysis cohorts.
Breast Cancer Ovarian Cancer Death Censored Total
N (%) 715 (37.1%) 62 (3.2%) 698 (36.3%) 450 (23.4%) 1925
Event age
mean (SD) 47.9 (12.8) 54.3 (11.3) 69.9 (18.2) 51.8 (16.3) 57.0 (18.6)
min, max 21.8, 94.0 30.0, 80.0 16.5, 109.5 19.7, 97.0 16.5, 109.5
BRCA Mutation
Noncarrier 31 (4.3%) 3 (4.8%) 17 (2.4%) 196 (43.6%) 247 (12.8%)
Carrier 373 (52.2%) 18 (29.0%) 10 (1.4%) 175 (38.9%) 576 (29.9%)
Untested 311 (43.5%) 41 (66.1%) 671 (96.1%) 79 (17.6%) 1102 (57.3%)
# of screening
0 566 (79.2%) 58 (46.8%) 685 (98.1%) 170 (37.8%) 1479 (76.8%)
1 107 (15.0%) 4 (3.2%) 7 (1%) 145 (32.2%) 263 (13.7%)
2 26 (3.6%) 58 (46.8%) 4 (0.6%) 45 (10.0%) 75 (3.9%)
3+ 16 (2.2%) 4 (3.2%) 2 (0.3%) 90 (20.0%) 108 (5.6%)
Surgery
None 683 (95.5%) 62 (100.0%) 689 (98.7%) 335 (74.4%) 1769 (91.9%)
BM 0 (0.0%) 0 (0.0%) 0 (0.0%) 8 (1.8%) 8 (0.4%)
BO 32 (4.5%) 0 (0.0%) 9 (1.3%) 83 (18.4%) 124 (6.4%)
Both 0 (0.0%) 0 (0.0%) 0 (0.0%) 24 (5.3%) 24 (1.3%)
BO for Bilateral Oophorectomy, BM for Bilateral Mastectomy and SD for Standard Deviation.
Tables 5.3 and 5.4 present descriptive statistics for the probands of BRCA1 and the
BRCA2 families. In terms of their study entry ages, event ages, BRCA mutation status
and the number of screenings and surgeries. We classify the probands into three sub-
groups: BC, OC and Unaffected. BC subgroup consists of the probands who are affected
by breast cancer before the study entry (77.5% in BRCA1, 79.6% in BRCA2). Their
mean event age and study entry age are 43 years and 48 years respectively. Probands
in OC subgroup are affected by ovarian cancer before study entry and their proportion
is relatively small compared to BC subgroup (6.2% in BRCA1, 2.7% in BRCA2). Unaf-
fected probands are included in the data without being affected by either cancer before
the study entry. Probands are all mutation carriers in both BRCA1 and BRCA1 families.
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The unaffected have more surgeries than BC or OC subgroups, in BRCA1, there are 2
BM, 23 BO and 21 cases with both of the surgeries. BRCA2 unaffected probands have
1, 22 and 12 cases for BM, BO and both surgeries, respectively. We have very lim-
ited number of women who undergo BO among BC subgroup (4.7% in BRCA1, 4.0%
in BRCA2). There is no BM among OC subgroup in both BRCA1 and BRCA2. About
a half of the probands do not have screenings (57.8% in BRCA1, 57.1% in BRCA2).
They commonly have only one screening (28.9% in BRCA1, 29.6% in BRCA2). A small
proportion of the probands has multiple screenings (13.3% in BRCA1, 13.2% in BRCA2).
In Table 5.5, we summarize the distribution of the ages at the first screening, BO and their
gap times in BRCA1 and BRCA2 families. Gap times between consecutive screenings are
also presented. Mean age of the first screenings is about 40 years in BRCA1 and 43 years
in BRCA2. Mean age of BO is about 46 years in BRCA1 and 47 years in BRCA2. Mean
gap time between the first and second screenings is about 9 years and that between the
second and third is about 6 years.
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Table 5.3: Descriptive statistics for the probands of BRCA1 positive families.
Breast Cancer Ovarian Cancer Unaffected Total
N (%) 386 (77.5%) 31 (6.2%) 81 (16.3%) 498
Study entry age
mean (SD) 44.7 (9.9) 53.6 (9.9) 39.9 (10.1) 44.5 (10.3)
min, max 24.0, 81.5 39.6, 79.8 22.4, 71.0 22.4, 81.5
Event age
mean (SD) 40.1 (8.2) 48.3 (8.4) 48.4 (11.5) 41.9 (9.5)
min, max 21.9, 66.7 36.0, 79.0 22.4, 79.5 21.9, 79.5
BRCA Mutation
Carrier 386 (100.0%) 31 (100.0%) 81 (100.0%) 498 (100.0%)
Noncarrier 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Untested 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
# of screening
0 249 (64.5%) 20 (64.5%) 19 (23.5%) 288 (57.8%)
1 114 (29.5%) 9 (29.0%) 21 (25.9%) 144 (28.9%)
2 17 (4.4%) 2 (6.5%) 12 (14.8%) 31 (6.2%)
3+ 6 (1.6%) 0 (0.0%) 29 (35.8%) 35 (7.0%)
Surgery
None 368 (95.3%) 31 (100.0%) 35 (43.2%) 434 (87.2%)
BM 0 (0.0%) 0 (0.0%) 2 (2.5%) 2 (0.4%)
BO 18 (4.7%) 0 (0.0%) 23 (28.4%) 41 (8.2%)
Both 0 (0.0%) 0 (0.0%) 21 (25.9%) 21 (4.2%)
BO for Bilateral Oophorectomy, BM for Bilateral Mastectomy
SD for Standard Deviation.
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Table 5.4: Descriptive statistics for the probands of BRCA2 positive families.
Breast Cancer Ovarian Cancer Unaffected Total
N (%) 301 (79.6%) 10 (2.7%) 67 (17.7%) 378
Study entry age
mean (SD) 47.6 (10.9) 53.2 (11.6) 46.6 (11.1) 47.5 (11.0)
min, max 22.0, 84.4 37.0, 76.3 22.6, 82.3 22.0, 84.4
Event age
mean (SD) 43.5 (9.3) 51.4 (11.8) 54.2 (12.8) 45.6 (10.9)
min, max 21.8, 74.0 35.0, 75.0 26.6, 86.3 21.8, 86.3
BRCA Mutation
Carrier 301 (100.0%) 10 (100.0%) 67 (100.0%) 378 (100.0%)
Noncarrier 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Untested 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
# of screening
0 198 (65.8%) 8 (80.0%) 10 (14.9%) 216 (57.1%)
1 88 (29.2%) 2 (20.0%) 22 (32.8%) 112 (29.6%)
2 13 (4.3%) 0 (0.0%) 8 (11.9%) 21 (5.6%)
3+ 2 (0.7%) 0 (0.0%) 27 (40.3%) 29 (7.7%)
Surgery
None 289 (96.0%) 10 (100.0%) 32 (47.8%) 331 (87.6%)
BM 0 (0.0%) 0 (0.0%) 1 (1.5%) 1 (0.3%)
BO 12 (4.0%) 0 (0.0%) 22 (32.8%) 34 (9.0%)
Both 0 (0.0%) 0 (0.0%) 12 (17.9%) 12 (3.2%)
BO for Bilateral Oophorectomy, BM for Bilateral Mastectomy
SD for Standard Deviation.
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Table 5.5: Descriptive statistics for the Mammographic Screening and Bilateral Oophorectomy
ages in years
BRCA1 BRCA2
Mean (SD)
First MS age 40.6 (12.4) 42.6 (13.2)
BO age 45.7 (10.4) 46.9 (10.3)
Gaptime
MS1 - MS2 9.0 (7.6) 9.2 (8.2)
MS2 - MS3 6.0 (4.3) 6.2 (4.9)
BO - MS 12.1 (10.2) 16.0 (14.7)
MS - BO 8.1 (6.9) 9.3 (8.3)
MS1,MS2 and MS3 stand for the first,
second and third Mammogrphic Screenings,
respectively, BO for Bilateral
Oophorectomy, SD for Standard Deviation.
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5.2 Model specification
5.2.1 Effects of bilateral oophorectomy and mammographic screen-
ings
We fit the shared frailty competing risks model with TVC discussed in Chapter 3 consid-
ering ovarian cancer and death as the competing risks for breast cancer. The conditional
cause-specific hazard functions for breast cancer, ovarian cancer and death, denoted as
h1,h2,h3, respectively, are expressed as follow:
h1(t|X ,z1) = h01(t)exp{βg,1G+go(Xo(t, to))+gs1(Xs1(t, ts1))+gs2(Xs2(t, ts2))+gs3(Xs3(t, ts3))}z1
h2(t|X ,z2) = h02(t)exp{βg,2G}z2
h3(t|X ,z3) = h03(t)exp{βg,3G}z3, (5.1)
where h0 j(t), j = 1,2,3, are the Weibull baseline hazard functions for event j, G is the
time-invarying covariate for binary mutation status, βg, j are the coefficient of G associ-
ated with event j. z j are the cause-specific shared frailty variables for event j. Xo(t, to)
and Xs(t, ts) are the time varying covariates for BO and MS, respectively, with surgery
age to and screening age ts; Xo(t) = 1 if t ≥ to, 0 otherwise and Xs(t) = 1 if t ≥ ts. Note
that BO and screening are associated with the risk of BC but not with the other compet-
ing risks.
The effect of BO, go(·), is defined in three ways: PE, ED, and CO, as follows:
go(Xo(t, to)) =

0 if t < to (PE,ED,CO)
βo if t ≥ to (PE)
βo · exp
{−ηo(t− to)} if t ≥ to (ED)
βo · exp
{−ηo(t− to)}+ηo,0 if t ≥ to (CO)
where βo is the effect of the BO, ηo is the decay rate parameter (ED and CO models) and
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ηo,0 is the decay convergence parameter (CO model).
For screening effects, we include up to three screenings by 3 TVCs:
Xs1(t, ts1), Xs2(t, ts2), Xs3(t, ts3), where ts1, ts2, ts3 are ages in years for the first, second
and third screening, respectively, and their effects are defined in three ways: PE, ED, and
CO, as follows:
gs1(Xs1(t, ts1)) =

0 if t < ts1 (PE,ED,CO)
βs1 if ts1 ≤ t < ts2 (PE)
βs1 · exp
{−ηs1(t− ts1)} if ts1 ≤ t < ts2 (ED)
βs1 · exp
{−ηs1(t− ts1)}+ηs1,0 if ts1 ≤ t < ts2 (CO)
0 if t ≥ ts2 (PE,ED,CO) ,
where the effect of the first screening, βs1 is present only until the second screening
occurs (PE model) and it decays with rate ηs1 (ED and CO models) and converges to ηs1,0
(CO model). Decay rate and convergence parameters associated with the first screening,
ηs1 and ηs1,0, are only defined if we assume ED and CO TVC functions. Effects of the
second and third screenings, gs2(·) and gs3(·) are defined similarly:
gs2(Xs2(t, ts2)) =

0 if t < ts2 (PE,ED,CO)
βs2 if ts2 ≤ t < ts3 (PE)
βs2 · exp
{−ηs2(t− ts2)} if ts2 ≤ t < ts3 (ED)
βs2 · exp
{−ηs2(t− ts2)}+ηs2,0 if ts2 ≤ t < ts3 (CO)
0 if t ≥ ts3 (PE,ED,CO) ,
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gs3(Xs3(t, ts3)) =

0 if t < ts3 (PE,ED,CO)
βs3 if t ≥ ts3 (PE)
βs3 · exp
{−ηs3(t− ts3)} if t ≥ ts3 (ED)
βs3 · exp
{−ηs3(t− ts3)}+ηs3,0 if t ≥ ts3 (CO) .
5.2.2 Missing mutation status
Binary mutation status variable is included in the model (5.1) as time invarying covari-
ate.As shown in Tables 5.1 and 5.2, mutation status is missing for about 60% of the
women, while most of the known mutation status are carriers (∼73% in BRCA1 and
∼70% in BRCA2). We impute missing mutation status based on empirical carrier proba-
bilities from the observed data and familial relationship and employ the robust variance
estimators as described in Section 3.4 for our proposed model with the imputed data.
Let G fi be the mutation status variable for family member i of the family f . We em-
pirically calculate the mutation carrier probability, ωg fi for individual i in family f from
observed mutation status, Go for each subset of the data which they share same disease
status D, other covariate values S and familial relationships to the proband:
ωg fi = P(G fi = g fi|D,S,G
o),
where g fi can take the value of 1 or 0 to represent a carrier or non-carrier of the mutated
gene. Then, we sample the carrier status based on this conditional carrier probability.
Imputation process was done single time due to computational burden for making infer-
ence from multiple imputations. We note that parameter estimates in our model from
five multiple imputations did not vary substantially.
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5.3 Analysis results
Table 5.6 presents the analysis results of the BRCA1 and BRCA2 mutation positive fam-
ilies in terms of the maximum likelihood estimates (MLEs), robust standard errors (SE)
and p-values for the model parameters. We chose the PE model for BO and ED for MS
as it provided the lowest Alkaike information criterion (AIC) value among possible com-
binations of TVC functions.
Figures 5.2 to 5.9 present cause-specific penetrance estimates. Figures 5.2 (BRCA1) and
5.6 (BRCA2) show breast and ovarian cancer penetrances for carriers and non-carriers
who have neither screenings nor BO. For BRCA1, Figures 5.3 and 5.4 show breast can-
cer penetrance given the single and three screenings and Figure 5.5 shows the breast
cancer penetrance given BO. For BRCA2, Figures 5.7 and 5.8 show breast cancer pene-
trance given the single and three screenings and Figure 5.9 shows the breast penetrance
given BO.
For the breast cancer penetrance estimation, we use ts1 = 40, ts2 = 45, ts3 = 50, to = 45,
which are close to the mean ages found in Table 5.5.
5.3.1 Relative risk
Log relative risks of the BRCA mutation, screenings and BO are presented in Table
5.6. Log relative risks of the mutation carrier towards breast cancer are βˆg1 = 2.25
(SˆE = 0.23) in BRCA1 and βˆg1 = 1.86 (SˆE = 0.20) for BRCA2. The result indicates that
being a mutation carrier increases the cause-specific hazard of developing breast cancer
by approximately 9.49 times compared to non-carrier and 6.42 times in BRCA2 adjusting
for the screenings, BO and familial correlation.
Log relative risks of BO for breast cancer is βˆo = −0.20 (SˆE = 0.20) for BRCA1 and
βˆo = −0.62 (SˆE = 0.22) for BRCA2. BO decreases the cause-specific hazard of devel-
58CHAPTER 5. APPLICATION TO HEREDITARY BREAST AND OVARIAN CANCER FAMILIES
Table 5.6: Modelling results for BRCA1/2 mutation positive families with a shared frailty com-
peting risk model with Permanent Exposure (PE) TVC for Bilateral Oophorectomy (BO) and
Exponential Decay (ED) for Mammographic Screenings (MS).
Shared frailty Competing Risk Model with PE BO and ED MS
BRCA1 families BRCA2 families
MLE SE p-value MLE SE p-value
λ1 0.0093 0.0004 < 0.001 0.0098 0.0003 < 0.001
ρ1 2.6041 0.0720 < 0.001 2.9918 0.0937 < 0.001
λ2 0.0084 0.0005 < 0.001 0.0053 0.0010 < 0.001
ρ2 3.1831 0.1435 < 0.001 2.3299 0.2902 < 0.001
λ3 0.0153 0.0001 < 0.001 0.0154 0.0002 < 0.001
ρ3 4.2225 0.1428 < 0.001 4.0877 0.1133 < 0.001
Breast Cancer
βg1 2.1786 0.1227 < 0.001 1.8606 0.2036 < 0.001
βs1 3.3494 0.2907 < 0.001 3.8261 0.2556 < 0.001
βs2 3.3548 0.4094 < 0.001 3.8273 0.4841 < 0.001
βs3 2.8169 0.7050 < 0.001 1.1431 0.2661 < 0.001
βo -0.1971 0.1984 0.3204 -0.6191 0.2210 0.0051
ηs1 2.8946 0.8464 < 0.001 1.6931 0.1945 < 0.001
ηs2 4.1197 1.4184 0.0037 1.3482 0.5250 0.0102
ηs3 2.7508 1.7201 0.1098 0.0136 0.0084 0.0574
k1 3.2566 0.2550 < 0.001 2.6625 0.5988 < 0.001
Ovarian Cancer
βg2 1.1757 0.2176 < 0.001 -0.9350 0.3432 0.0064
k2 1.6882 0.2092 ¡0.001 0.1993 0.0636 0.0017
Death
βg3 -0.4401 0.1515 0.0037 -0.6806 0.1158 < 0.001
MLE is Maximum Likelihood Estimates, SE is robust Standard Error.
oping breast cancer by approximately 0.76 times in BRCA1 and 0.54 times in BRCA2
adjusting for the screenings, mutation status and familial correlation.
Screenings drastically increase cause-specific hazard of developing breast cancer. Log
relative risks of the first, second and third screenings are βˆs1 = 2.18 (SˆE = 0.12), βˆs2 =
3.35 (SˆE = 0.29), βˆs3 = 2.82 (SˆE = 0.71) in BRCA1 and βˆs1 = 3.83 (SˆE = 0.26), βˆs2 =
3.83 (SˆE = 0.48), βˆs3 = 1.14 (SˆE = 0.27) in BRCA2. However, the effects of screenings
decay with time at relatively high rates.
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There is a positive association between BRCA mutation and the cause-specific hazard of
developing ovarian cancer in BRCA1, βˆg2 = 1.18 (SˆE = 0.22). Being a mutation carrier
increases the cause-specific hazard of developing ovarian cancer by approximately 3.25
times compared to non-carrier. In contrast, BRCA2 mutation shows negative association
with ovarian cancer βˆg2 =−0.94 (SˆE = 0.34).
The estimates of frailty parameters k1 and k2 are 3.26 (95% CI between 2.76 and 3.76)
and 1.69 (95% CI between 1.28 and 2.10) in BRCA1 and 2.66 (95% CI between 1.49
and 3.84) and 0.19 (95% CI between 0.075 and 0.32) in BRCA2. They correspond to
Kendall’s τ around 0.13 for breast cancer and 0.23 for ovarian cancer in BRCA1 and
0.16 for breast cancer and 0.72 for ovarian cancer in BRCA2.
5.3.2 BRCA1 penetrance estimations
Figure 5.2 shows the estimated cause-specific penetrance functions for breast cancer
(left) and ovarian cancer (right) for those who have no screenings nor BO for BRCA1
mutation positive families. Solid red lines are penetrance estimates for mutation carriers
and blue lines are for non-carriers. Dotted lines are 95% confidence intervals. Breast
cancer penetrance by age 70 is estimated around 60.3% (95% CI between 55.9% and
64.6%) for mutation carriers while for non-carriers, it is 11.6% (95% CI between 9.9%
and 13.3%). Ovarian cancer penetrance at age 70 is much lower than breast cancer
penetrance, 11.4% (95% CI between 9.0% and 13.9%) for carriers and 5.4% (95% CI
between 4.2% and 6.6%) for non-carriers.
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Figure 5.2: (BRCA1) Penetrance estimations for breast cancer (left panel) and ovarian cancer
(right panel) conditioning no screening activities and surgeries. Solid red lines are penetrance
estimates for mutation carriers and blue lines are for non-carriers. Dotted line represents 95%
confidence intervals.
Figure 5.3 presents breast cancer penetrance estimates for those who have single screen-
ing and no BO from BRCA1. The left most plot is penetrance estimate for those without
screening and is equivalent to the left plot of Figure 5.2. The remaining three plots to
the right show penetrances given that the first screening occured at age 35, 40 and 45,
respectively.
Given that the first screening occured at age 35, penetrance by age 70 is estimated around
67.4% (95% CI between 62.5% and 72.3%) for mutation carriers while for non-carriers,
it is 12.3% (95% CI between 10.5% and 14.2%). With the first screening at age 45,
penetrance by age 70 is estimated around 75.5% (95% CI between 69.5% and 81.5%)
for mutation carriers and 12.8% (95% CI between 10.9% and 14.8%) for non-carriers.
Penetrance of the non-carriers is not substantially increased by the age of screening,
whereas penetrance of the carriers who have the first screening earlier in life have lower
penetrance. This could be an indication that having a screening visit early is beneficial.
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Figure 5.3: (BRCA1) Breast cancer (BC) penetrance estimations with the first mammographic
screenings. The left most plot represents BC penetrance with no screening. To the right, they
describe penetrance estimation with the first screening at age 35, 40 and 45, respectively. Solid
red lines are penetrance estimates for mutation carriers and blue lines are for non-carriers.
Dotted line represents 95% confidence intervals.
Figure 5.4 shows breast cancer penetrance for those who have three consecutive screen-
ings for BRCA1 positive families. The left most plot depicts the penetrance estimate
without any screening. Plots in the middle and the right show penetrance estimates given
that the first, second and third screening occured at ages 30, 35 and 40, and at ages 35,
40 and 45, respectively.
Similar to Figure 5.3, those who have the first screening early have lower penetrance
compared to those lagged by 5 years. As well, penetrance is much higher if the subjects
have multiple screenings (90.5% vs 67.4%) compared to those with single screening even
though both groups have the first screen at age of 35.
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Figure 5.4: (BRCA1) Breast cancer (BC) penetrance estimations with three mammographic
screenings. The left most plot represents BC penetrance with no screening. To the right, they
describe penetrance estimations with the first screening at age 30 and 35 with the consecutive
screening gap times of 5 years. Solid red lines are penetrance estimates for mutation carriers
and blue lines are for non-carriers. Dotted line represents 95% confidence intervals.
Figure 5.5 presents breast cancer penetrance for subgroups who have BO for BRCA1
positive families. The left most plot is the penetrance function estimated for those with-
out BO, which is equivalent to the left plot in Figure 5.2. Remaining three plots to the
right are penetrances given that BO occured at age 40, 45 and 50, respectively.
Given that BO occured at age 40, penetrance by age 70 is estimated around 64.9% (95%
CI between 54.1% and 75.8%) for mutation carriers while for non-carriers, it is 9.5%
(95% CI between 6.5% and 12.5%). Given that BO occured at age 45, penetrance by
age 70 is estimated around 68.1% (95% CI between 57.5% and 78.7%) for the mutation
carriers while for non-carriers, it is 9.6% (95% CI between 6.8% and 12.3%). Given
that BO occured at age 50, penetrance by age 70 is estimated around 70.4% (95% CI
between 60.3% and 80.5%) for the mutation carriers while for non-carriers, it is 9.7%
(95% CI between 7.3% and 12.1%). Even though estimated BO effect, βˆo =−0.20, has
negative but statistically insignificant association with cause-specific hazard of breast
cancer, it turns out that the effect does not affect the penetrance in the same direction.
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This is a well known property in cause-specific hazard approach. There is no one-to-one
correspondence between hazard and penetrance functions.
Figure 5.5: (BRCA1) Breast cancer (BC) penetrance estimations with bilateral oophorectomy.
The left most plot represents BC penetrance with no BO. To the right, they describe penetrance
estimation with the BO at age 40, 45 and 50. Solid red lines are penetrance estimates for
mutation carriers and blue lines are for non-carriers. Dotted line represents 95% confidence
intervals.
5.3.3 BRCA2 penetrance estimations
Figure 5.6 shows the estimated cause-specific penetrance for breast cancer (left) and
ovarian cancer (right) of the subgroups who do not have screenings and BO for BRCA2
mutation positive families. Breast cancer penetrance by age 70 is estimated around
53.0% (95% CI between 48.0% and 57.9%) for mutation carriers while for non-carriers,
it is 11.5% (95% CI between 9.6% and 13.4%). Ovarian cancer penetrance at age 70 is
much lower than breast cancer penetrance, 1.4% (95% CI between 0.6% and 2.2%) for
carriers and 4.0% (95% CI between 2.6% and 5.4%) for non-carriers. It is quite peculiar
that the carrier exhibits lower penetrance than non-carriers and further investigation is
required.
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Figure 5.6: (BRCA2) Penetrance estimations for breast cancer (left panel) and ovarian cancer
(right panel) conditioning no screening activities and surgeries. Solid red lines are penetrance
estimates for mutation carriers and blue lines are for non-carriers. Dotted line represents 95%
confidence intervals.
Figure 5.7 presents breast cancer penetrance estimates for subgroups who have single
screening and no BO for BRCA2. The left most plot is the penetrance function estimated
for those without screening, which is equivalent to the left plot in Figure 5.6. Remaining
three plots to the right show penetrances given that the first screening occured at age 35,
40 and 45, respectively.
Given that the first screening occured at age 35, penetrance by age 70 is estimated around
56.8% (95% CI between 51.5% and 62.1%) for mutation carriers while for non-carriers,
it is 12.2% (95% CI between 10.1% and 14.3%). Given that the first screening occured
at age 45, penetrance by age 70 is estimated around 62.2% (95% CI between 56.0% and
68.4%) for mutation carriers while for non-carriers, it is 12.8% (95% CI between 10.6%
and 15.0%).
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Figure 5.7: (BRCA2) Breast cancer (BC) penetrance estimations with the first mammographic
screenings. The left most plot represents BC penetrance with no screening. To the right, they
describe penetrance estimation with the first screening at age 35, 40 and 45, respectively. Solid
red lines are penetrance estimates for mutation carriers and blue lines are for non-carriers.
Dotted line represents 95% confidence intervals.
Figure 5.8 shows breast cancer penetrance for those who have three consecutive screen-
ings for BRCA2 positive families. The left most plot is the penetrance function estimated
for those without any screening, which is equivalent to the left plot in Figure 5.6. Plots in
the middle and the right show penetrance estimates given that the first, second and third
screening occured at ages 30, 35 and 40, and at ages 35, 40 and 45, respectively.
Given that the first, second and third screenings occured at age 30,35 and 40, the pen-
etrance by age 70 is estimated around 88.2% (95% CI between 74.0% and 88.6%) for
mutation carriers while for non-carriers, it is 13.4% (95% CI between 11.3% and 15.6%).
Given that the first, second and third screenings occured at age 35, 40 and 45, penetrance
by age 70 is estimated around 90.5% (95% CI between 81.6% and 99.5%) for mutation
carriers while for non-carriers, it is 14.1% (95% CI between 11.7% and 16.4%).
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Figure 5.8: (BRCA2) Breast cancer (BC) penetrance estimations with three mammographic
screenings. The left most plot represents BC penetrance with no screening. To the right, they
describe penetrance estimations with the first screening at age 30 and 35 with the consecutive
screening gap times of 5 years. Solid red lines are penetrance estimates for mutation carriers
and blue lines are for non-carriers. Dotted line represents 95% confidence intervals.
Figure 5.9 presents breast cancer penetrance for subgroups who have BO for BRCA2
positive families. The left most plot is estimate without BO and equivalent to the left
plot in Figure 5.2. Remaining three plots to the right are penetrances given that BO oc-
cured at age 40, 45 and 50, respectively.
In BRCA2, BO decreases the cause-specific penetrance by age 70 contrary to BRCA1.
Given that BO occured at age 40, penetrance by age 70 is estimated around 40.1% (95%
CI between 29.5% and 50.8%) for mutation carriers while for non-carriers, it is 7.0%
(95% CI between 4.4% and 9.7%). Given that BO occured at age 50, penetrance by
age 70 is estimated around 45.2% (95% CI between 35.9% and 54.6%) for the mutation
carriers while for non-carriers, it is 7.7% (95% CI between 5.5% and 9.9%). Similarly to
the screening, earlier BO is beneficial since the life-time risk of breast cancer is reduced
by about 5%.
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Figure 5.9: (BRCA2) Breast cancer (BC) penetrance estimations with bilateral oophorectomy.
The left most plot represents BC penetrance with no BO. To the right, they describe penetrance
estimation with the BO at age 40, 45 and 50. Solid red lines are penetrance estimates for
mutation carriers and blue lines are for non-carriers. Dotted line represents 95% confidence
intervals.
5.3.4 Summary
In both BRCA1 and BRCA2 families, there are statistically significant associations be-
tween mutation and cause-specific hazard of each cancer (p < 0.001). Being mutation
carrier increases the cause-specific penetrance for breast cancer in BRCA1/2. Ovarian
cancer penetrance is also affected by mutation status but in an opposite direction for
BRCA1/2. BO has statistically significant negative association with cause-specific haz-
ard of breast cancer in BRCA2. BO decreases the breast cancer penetrance by age at 70
(95% CI 0.48-0.58 for non-BO vs 0.29-0.51 for BO). However, it slightly increases pen-
etrance in BRCA1 (95% CI 0.56-0.64 for non-BO vs 0.54-0.76 for BO). MS is associated
with the increase in both cause-specific hazard and penetrance of breast cancer possibly
due to the reason that MS detects cancer. However, their effects decay to zero very fast.
Failure times for ovarian cancer have stronger familial correlations than those of breast
cancer.
Chapter 6
Discussion
6.1 Summary
This thesis proposes a shared frailty model extended to competing risks framework with
time varying covariates for data arising from family studies. A shared frailty model
is specified to account for familial residual dependence and an ascertainment-corrected
likelihood is used to correct selection bias in family studies. We also provide the cause-
specific cumulative incidence function that estimates age-specific risks of disease with
time-varying covariates. Application of the model is not limited to the illustrative study
on BRCA mutation families. Rather, it can be applied to any study when one is con-
cerned with clustered failure times having multiple endpoints along with time varying
binary covariates. However, further work is required to incorporate time dependent con-
tinuous or categorical variables.
We evaluated the performance of the estimators for the parameters in the model and
the plug-in estimator of the penetrance function via simulations. The simulation results
show that model parameters and penetrance estimators work well regardless of the num-
ber of families, degrees of familial dependence and the types of time varying covariate
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functions. However, with n= 250 families, the model with the CO TVC exhibited con-
vergence issues in about 5% of the total simulations. PE and ED TVC models did not
have any convergence issues. This is possibly due to the increased number of parameters
or the presence of multiple local maxima in partial likelihood function noted by Cox and
Oakes (1984). Further investigation is required.
Analysis of the BRCA families shows that the mutation carrier is exposed to much higher
risk of breast cancer and aligns with the previous studies. Risk of ovarian cancer is also
elevated but in lesser degree than breast cancer. BO is associated with decrease in cause-
specific hazard of breast cancer in BRCA1/2 but there is no statistical significance in
BRCA1. In BRCA1, this association does not correspond to the penetrance because pen-
etrance by age 70 is slightly increased while both cause-specfic hazard and penetrance
decrease with BO in BRCA2. We did not find any improvement in terms of AIC when
we considered BO as ED and CO compared to PE. Their decay rate parameters converge
to very small value indicating that the effect does not change much over time. When we
handle the BO as TIC, it has much stronger association with breast cancer. On the other
hand, the estimated effect of MS varies substantially with the choice of TVC function.
Interestingly, when MS is handled as TIC, there is a statistically significant protective
effect against breast cancer. MS as TVC unveils totally different association with breast
cancer as it substantially increases the cause-specific hazard and penetrance but this ef-
fect mostly diminishes within about a year. Finally, failure times for ovarian cancer have
stronger familial correlations than those of breast cancer.
6.2 Limitation and further work
Our analysis is limited to the first breast cancer in the presence of competing risks. How-
ever, successive events after the first event are also of interest in analysis of cancer co-
horts. For instance, in evaluation of the screenings efficiency, one might be interested
in the protective effect of the screenings leading to lower mortality rate after the first
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breast cancer detection. Also, mortality rates could be different between cohorts who
are affected by the breast and ovarian cancer. We have only considered the parametric
approach in modelling the baseline hazard but in practice, use of a piece-wise constant
baseline hazard function could be more desirable in some of the applications providing
more flexible assumptions on baseline hazard.
The competing risk framework is not only limited to the cause-specific hazard approach.
Subdistribution hazard and mixture model have their own advantages in terms of inter-
pretability. For modeling the familial dependence, we only considered the independent
frailty variables for the breast and ovarian cancer, but correlated frailties could better ac-
count for more complex dependence structure. In addtion, indepedent frailties assump-
tion imposed in the analysis of Chapter 5 should be validated by assessing the correlated
frailty model. Alternatively, a copula approach could also be considered beside frailty
model.
In analysis of BRCA families, we treated the MS and BO as simple binary TVC assum-
ing no measurement error and relaxed assumption on internal TVC. This is an important
assumption when incorporating the TVC to the Cox model. Kalbfleisch and Prentice
(2002) classified external and internal TVC. The former is often referred as exogeneous
TVC since its path over time is not dependent on the subjects such as weather condition
or predetermined drug dosage. More formally, the exogeneity condition states that the
external TVC is a predictable process and the occurrence of the failure at time t does
not affect the value of TVC for any time s ≥ t (Rizopoulos, 2012). In contrast, internal
or endogeneous TVC is the measurement taken on the subjects. It complicates the sta-
tistical analysis since its path is affected by the occurence of the failure. For example,
when the failure is defined as the death of the subject, then the existence of the TVC
before infinitesimal time t ensures the survival probability of the subject at t to be 1 and
failure time at t corresponds to the nonexistence of the TVC at s ≥ t. Thus, the hazard
function can be only defined up to time t, the existence time of the covariate process,
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but not further, and the corresponding survival function is defined up to time t as well.
We assume that the violation of the exogeneity condition is minimal for the MS and BO
because their paths are not directly related to the event of interest.
In addition, we did not include other environmental risk factors potentially associated
with breast cancer in women anticipating they have the minimal effects on the study
results. Laden and Hunter (1998) investigated four potential risk factors in US women
population: ionizing radiation, organochlorines, electromotive forces and smoking. They
found that associations between the four pollutants and breast cancer are rather incon-
clusive and are substantially weaker compared to those of genetic factors.
Further work should involve more complex modelling when one is interested in incor-
porating such repeated measurements of longitudinal data. Potential candidates of those
measurements could be the number of circulating tumor cells, immune response to a
vaccine or a genetic biomarker. They are susceptible to measurement error and more
difficult to relax the internal TVC assumption. Then, a linear mixed model can be con-
sidered for the longitudinal data. Joint modelling is a method to simultaneously model
longitudinial data and the failure times not only accounting for measurement error but
also to account for any association between longitudinal data and failure times (Ibrahim
et al., 2010).
Appendix A
Additional simulation results
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Table A.1: (1000 families) Empirical properties of the parameter and penetrance estimators
for shared frailty competing risks model with Permanent Exposure TVC under low (k1 = 7),
medium (k1 = 3.5) and high (k1 = 1) familial dependence of the event times for event 1 based
on 500 simulations.
Permanent Exposure Model
True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
log(λ1) -4.83 -0.01 0.04 0.04 0.95 -4.83 0.00 0.04 0.04 0.95 -4.83 0.00 0.04 0.04 0.96
log(ρ1) 0.88 0.00 0.02 0.02 0.96 0.88 0.00 0.02 0.02 0.95 0.88 0.00 0.02 0.02 0.97
log(λ2) -4.96 0.00 0.06 0.07 0.96 -4.96 -0.01 0.07 0.07 0.96 -4.96 0.00 0.07 0.07 0.96
log(ρ2) 1.12 0.00 0.05 0.05 0.95 1.12 0.00 0.05 0.05 0.97 1.12 0.00 0.05 0.05 0.95
βs 0.67 0.00 0.08 0.08 0.96 0.67 0.00 0.08 0.08 0.94 0.67 0.00 0.08 0.08 0.94
βg1 1.95 0.01 0.08 0.08 0.94 1.95 0.00 0.08 0.08 0.94 1.95 0.00 0.08 0.08 0.94
βg2 1.19 0.00 0.15 0.16 0.97 1.19 0.01 0.16 0.16 0.95 1.19 0.01 0.16 0.17 0.96
log(k1) 1.95 0.12 0.62 0.58 0.95 1.25 0.05 0.36 0.32 0.96 0.00 0.01 0.17 0.18 0.96
log(k2) 1.06 0.48 1.95 0.98 0.88 1.06 0.38 1.38 1.01 0.91 1.06 0.54 2.15 1.00 0.88
Cause-specific penetrance (%) given tsc = 35
Cause 1
F1(40;S= 0,G= 0) 2.06 -0.01 0.19 0.19 0.94 2.05 -0.01 0.20 0.19 0.94 2.04 0.00 0.19 0.20 0.95
F1(40;S= 1,G= 0) 2.85 0.00 0.26 0.25 0.93 2.84 -0.01 0.26 0.25 0.94 2.81 0.00 0.27 0.27 0.93
F1(40;S= 0,G= 1) 13.43 0.02 0.73 0.75 0.95 13.31 -0.02 0.81 0.79 0.94 12.72 0.00 0.89 0.92 0.95
F1(40;S= 1,G= 1) 18.06 0.07 1.01 1.03 0.95 17.83 -0.02 1.09 1.08 0.95 16.80 0.01 1.21 1.23 0.96
F1(50;S= 0,G= 0) 4.53 -0.02 0.39 0.37 0.93 4.52 -0.01 0.40 0.38 0.94 4.45 -0.01 0.39 0.40 0.96
F1(50;S= 1,G= 0) 7.56 -0.01 0.68 0.65 0.95 7.52 -0.02 0.68 0.66 0.94 7.32 -0.01 0.69 0.70 0.94
F1(50;S= 0,G= 1) 27.07 0.00 1.27 1.31 0.96 26.56 -0.01 1.42 1.39 0.95 24.38 0.01 1.59 1.63 0.95
F1(50;S= 1,G= 1) 40.70 0.10 2.13 2.18 0.96 39.60 -0.03 2.26 2.27 0.94 35.11 0.02 2.40 2.44 0.95
F1(60;S= 0,G= 0) 8.07 -0.05 0.66 0.64 0.93 8.02 -0.01 0.68 0.65 0.95 7.80 -0.02 0.66 0.68 0.96
F1(60;S= 1,G= 0) 14.05 -0.04 1.20 1.17 0.94 13.91 -0.03 1.21 1.18 0.93 13.26 -0.03 1.20 1.21 0.94
F1(60;S= 0,G= 1) 42.42 -0.04 1.81 1.87 0.96 41.23 0.01 2.01 1.99 0.95 36.41 0.03 2.23 2.30 0.95
F1(60;S= 1,G= 1) 61.28 0.04 2.67 2.74 0.95 58.99 -0.04 2.85 2.88 0.94 50.29 0.03 3.06 3.14 0.95
F1(70;S= 0,G= 0) 12.56 -0.09 0.99 0.97 0.94 12.45 -0.01 1.02 0.98 0.95 11.93 -0.02 0.99 1.02 0.95
F1(70;S= 1,G= 0) 21.92 -0.08 1.78 1.74 0.95 21.58 -0.03 1.79 1.76 0.94 20.09 -0.04 1.73 1.76 0.95
F1(70;S= 0,G= 1) 56.52 -0.09 2.19 2.27 0.96 54.51 0.03 2.41 2.42 0.96 46.80 0.03 2.67 2.77 0.96
F1(70;S= 1,G= 1) 75.63 -0.04 2.57 2.66 0.95 72.59 -0.06 2.84 2.88 0.95 61.08 0.03 3.27 3.38 0.96
Cause 2
F2(40;S= 0,G= 0) 0.46 0.00 0.07 0.08 0.94 0.46 0.00 0.07 0.08 0.96 0.46 0.00 0.07 0.07 0.94
F2(40;S= 1,G= 0) 0.46 0.00 0.07 0.07 0.94 0.46 0.00 0.07 0.07 0.96 0.46 0.00 0.07 0.07 0.94
F2(40;S= 0,G= 1) 1.40 0.00 0.15 0.15 0.95 1.41 0.01 0.15 0.15 0.96 1.41 0.00 0.15 0.16 0.96
F2(40;S= 1,G= 1) 1.38 0.00 0.15 0.15 0.95 1.38 0.01 0.15 0.15 0.96 1.39 0.00 0.15 0.15 0.96
F2(50;S= 0,G= 0) 1.27 0.01 0.17 0.18 0.95 1.27 -0.01 0.17 0.18 0.95 1.27 0.00 0.17 0.18 0.94
F2(50;S= 1,G= 0) 1.25 0.01 0.17 0.17 0.95 1.25 -0.01 0.17 0.17 0.95 1.25 0.00 0.17 0.17 0.95
F2(50;S= 0,G= 1) 3.53 0.00 0.31 0.30 0.94 3.54 0.01 0.30 0.30 0.95 3.58 -0.01 0.31 0.32 0.96
F2(50;S= 1,G= 1) 3.21 0.00 0.28 0.27 0.94 3.23 0.01 0.28 0.27 0.95 3.31 -0.01 0.28 0.29 0.96
F2(60;S= 0,G= 0) 2.67 0.01 0.33 0.34 0.96 2.67 -0.01 0.34 0.34 0.95 2.67 -0.01 0.34 0.35 0.94
F2(60;S= 1,G= 0) 2.57 0.01 0.32 0.33 0.96 2.57 -0.01 0.33 0.33 0.95 2.58 -0.01 0.33 0.34 0.94
F2(60;S= 0,G= 1) 6.48 0.01 0.52 0.52 0.95 6.53 0.01 0.51 0.53 0.95 6.74 0.00 0.55 0.56 0.96
F2(60;S= 1,G= 1) 5.32 0.00 0.43 0.43 0.95 5.42 0.01 0.43 0.44 0.95 5.83 -0.01 0.47 0.47 0.95
F2(70;S= 0,G= 0) 4.73 0.03 0.58 0.61 0.96 4.73 -0.02 0.60 0.61 0.96 4.74 0.00 0.61 0.62 0.94
F2(70;S= 1,G= 0) 4.45 0.02 0.55 0.57 0.95 4.45 -0.02 0.57 0.57 0.95 4.49 0.00 0.58 0.59 0.94
F2(70;S= 0,G= 1) 9.68 0.02 0.80 0.82 0.95 9.85 0.02 0.77 0.83 0.97 10.52 0.01 0.88 0.91 0.96
F2(70;S= 1,G= 1) 7.12 0.00 0.61 0.63 0.96 7.42 0.02 0.62 0.65 0.96 8.56 0.00 0.72 0.73 0.95
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Table A.2: (1000 families) Empirical properties of the parameter and penetrance estimators
for shared frailty competing risks model with Exponential Decay TVC under low (k1 = 7),
medium (k1 = 3.5) and high (k1 = 1) familial dependence of the event times for event 1 based
on 500 simulations.
Exponential Decay Model
True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
log(λ1) -4.83 0.00 0.04 0.04 0.95 -4.83 0.00 0.04 0.04 0.95 -4.83 0.00 0.04 0.04 0.95
log(ρ1) 0.83 0.00 0.02 0.02 0.95 0.83 0.00 0.02 0.02 0.95 0.83 0.00 0.02 0.02 0.95
log(λ2) -4.96 -0.01 0.06 0.07 0.96 -4.96 0.00 0.06 0.07 0.96 -4.96 0.00 0.06 0.07 0.98
log(ρ2) 1.08 0.00 0.04 0.05 0.96 1.08 0.00 0.04 0.05 0.96 1.08 0.00 0.04 0.04 0.96
βs 1.87 0.01 0.18 0.18 0.94 1.87 0.01 0.16 0.18 0.96 1.87 0.02 0.17 0.17 0.95
βg1 1.86 0.00 0.08 0.08 0.96 1.86 0.00 0.08 0.08 0.96 1.86 0.01 0.08 0.08 0.96
βg2 1.22 0.00 0.15 0.15 0.94 1.22 0.02 0.14 0.15 0.97 1.22 0.01 0.15 0.15 0.96
log(k1) 1.95 0.16 0.91 0.59 0.94 1.25 0.04 0.32 0.32 0.95 0.00 0.02 0.16 0.17 0.97
log(k2) 1.18 0.34 1.18 0.92 0.91 1.18 0.36 1.58 0.97 0.90 1.18 0.41 1.37 1.04 0.92
log(η) -1.28 0.01 0.21 0.21 0.95 -1.28 0.00 0.20 0.22 0.96 -1.28 0.03 0.20 0.21 0.96
Cause-specific penetrance (%) given tsc = 35
Cause 1
F1(40;S= 0,G= 0) 2.43 0.00 0.20 0.21 0.96 2.42 0.00 0.21 0.21 0.95 2.40 0.02 0.22 0.22 0.95
F1(40;S= 1,G= 0) 4.21 0.00 0.39 0.42 0.95 4.20 0.02 0.42 0.42 0.94 4.14 0.00 0.41 0.43 0.96
F1(40;S= 0,G= 1) 14.36 -0.03 0.73 0.78 0.97 14.21 -0.01 0.79 0.82 0.96 13.55 0.14 0.93 0.94 0.95
F1(40;S= 1,G= 1) 23.47 -0.05 1.53 1.61 0.96 23.09 0.02 1.59 1.63 0.96 21.41 0.10 1.63 1.68 0.95
F1(50;S= 0,G= 0) 5.16 0.01 0.40 0.41 0.96 5.14 0.01 0.40 0.42 0.95 5.04 0.03 0.43 0.44 0.95
F1(50;S= 1,G= 0) 7.30 0.02 0.61 0.66 0.95 7.26 0.05 0.66 0.67 0.95 7.08 0.01 0.65 0.68 0.96
F1(50;S= 0,G= 1) 27.84 -0.06 1.21 1.31 0.97 27.30 -0.04 1.31 1.39 0.96 25.01 0.21 1.58 1.60 0.95
F1(50;S= 1,G= 1) 36.87 -0.03 1.95 2.13 0.98 35.95 0.08 2.11 2.19 0.96 32.16 0.15 2.16 2.25 0.96
F1(60;S= 0,G= 0) 8.91 0.01 0.66 0.68 0.96 8.85 0.01 0.65 0.69 0.95 8.59 0.04 0.70 0.72 0.95
F1(60;S= 1,G= 0) 10.98 0.03 0.82 0.88 0.96 10.89 0.06 0.87 0.89 0.95 10.49 0.03 0.87 0.90 0.96
F1(60;S= 0,G= 1) 42.49 -0.09 1.69 1.82 0.98 41.29 -0.06 1.82 1.93 0.96 36.44 0.26 2.14 2.19 0.95
F1(60;S= 1,G= 1) 49.34 -0.03 2.05 2.26 0.98 47.76 0.06 2.28 2.36 0.95 41.55 0.22 2.45 2.55 0.95
F1(70;S= 0,G= 0) 13.55 0.01 0.99 1.01 0.96 13.42 0.01 0.96 1.02 0.95 12.82 0.05 1.02 1.04 0.95
F1(70;S= 1,G= 0) 15.49 0.03 1.09 1.16 0.96 15.32 0.06 1.13 1.17 0.95 14.54 0.04 1.15 1.18 0.95
F1(70;S= 0,G= 1) 55.65 -0.10 2.03 2.19 0.98 53.68 -0.08 2.20 2.31 0.96 46.14 0.27 2.53 2.60 0.95
F1(70;S= 1,G= 1) 60.49 -0.05 2.15 2.36 0.97 58.24 0.02 2.42 2.49 0.95 49.69 0.25 2.68 2.78 0.95
Cause 2
F2(40;S= 0,G= 0) 0.59 0.00 0.09 0.09 0.94 0.59 -0.01 0.08 0.09 0.96 0.59 0.00 0.09 0.09 0.94
F2(40;S= 1,G= 0) 0.59 0.00 0.09 0.09 0.94 0.59 -0.01 0.08 0.09 0.96 0.59 0.00 0.09 0.09 0.94
F2(40;S= 0,G= 1) 1.86 -0.01 0.18 0.18 0.95 1.86 0.00 0.18 0.18 0.94 1.86 0.01 0.18 0.19 0.96
F2(40;S= 1,G= 1) 1.78 -0.01 0.17 0.17 0.95 1.78 0.00 0.17 0.17 0.94 1.80 0.01 0.17 0.18 0.96
F2(50;S= 0,G= 0) 1.55 -0.01 0.19 0.20 0.94 1.55 -0.02 0.19 0.20 0.96 1.56 0.00 0.20 0.20 0.94
F2(50;S= 1,G= 0) 1.52 -0.01 0.19 0.19 0.94 1.53 -0.02 0.18 0.19 0.96 1.53 0.00 0.19 0.20 0.94
F2(50;S= 0,G= 1) 4.42 -0.02 0.34 0.34 0.95 4.44 0.01 0.34 0.34 0.95 4.49 0.01 0.36 0.36 0.96
F2(50;S= 1,G= 1) 3.99 -0.02 0.31 0.30 0.95 4.02 0.01 0.31 0.31 0.95 4.12 0.01 0.33 0.32 0.95
F2(60;S= 0,G= 0) 3.14 -0.02 0.36 0.38 0.95 3.14 -0.03 0.36 0.38 0.97 3.14 -0.01 0.37 0.39 0.95
F2(60;S= 1,G= 0) 3.07 -0.02 0.35 0.37 0.95 3.07 -0.03 0.35 0.37 0.97 3.07 -0.01 0.36 0.38 0.95
F2(60;S= 0,G= 1) 7.81 -0.04 0.56 0.57 0.95 7.87 0.03 0.57 0.58 0.97 8.13 0.02 0.63 0.62 0.94
F2(60;S= 1,G= 1) 6.90 -0.03 0.50 0.50 0.96 6.99 0.01 0.51 0.51 0.96 7.38 0.02 0.56 0.55 0.95
F2(70;S= 0,G= 0) 5.39 -0.03 0.60 0.64 0.95 5.39 -0.05 0.61 0.65 0.96 5.41 -0.01 0.62 0.66 0.96
F2(70;S= 1,G= 0) 5.26 -0.03 0.58 0.63 0.95 5.26 -0.05 0.60 0.63 0.95 5.28 -0.01 0.60 0.65 0.96
F2(70;S= 0,G= 1) 11.38 -0.04 0.82 0.86 0.96 11.57 0.04 0.86 0.88 0.96 12.34 0.03 0.98 0.96 0.94
F2(70;S= 1,G= 1) 9.97 -0.04 0.74 0.76 0.96 10.22 0.02 0.77 0.79 0.95 11.20 0.03 0.88 0.87 0.94
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Table A.3: (1000 families) Empirical properties of the parameter and penetrance estimators for
shared frailty competing risks model with Cox and Oakes TVC under low (k1 = 7), medium
(k1 = 3.5) and high (k1 = 1) familial dependence of the event times for event 1 based on 500
simulations.
Cox and Oakes Model
True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
log(λ1) -4.83 0.00 0.03 0.04 0.95 -4.83 0.00 0.03 0.04 0.98 -4.83 0.00 0.03 0.04 0.96
log(ρ1) 0.83 0.00 0.02 0.02 0.95 0.83 0.00 0.02 0.02 0.98 0.83 0.00 0.02 0.02 0.96
log(λ2) -4.96 0.00 0.05 0.06 0.95 -4.96 -0.01 0.05 0.06 0.96 -4.96 0.00 0.05 0.06 0.97
log(ρ2) 1.07 0.00 0.03 0.04 0.97 1.07 0.00 0.03 0.04 0.97 1.07 0.00 0.03 0.04 0.97
βs 1.52 0.02 0.26 0.30 0.93 1.52 0.04 0.24 0.31 0.96 1.52 0.04 0.23 0.30 0.96
βg1 2.08 0.01 0.07 0.08 0.97 2.08 0.01 0.07 0.08 0.95 2.08 0.00 0.07 0.08 0.95
βg2 1.57 0.00 0.12 0.14 0.95 1.57 0.01 0.11 0.15 0.97 1.57 0.01 0.12 0.15 0.96
log(k1) 1.95 0.03 0.43 0.51 0.94 1.25 0.04 0.25 0.30 0.97 0.00 0.00 0.13 0.16 0.97
log(k2) 1.26 0.27 0.72 0.92 0.93 1.26 0.14 0.71 0.83 0.92 1.26 0.19 0.68 0.87 0.92
log(η) -0.18 0.02 0.35 0.42 0.93 -0.18 0.03 0.33 0.43 0.94 -0.18 0.04 0.36 0.43 0.94
η0 0.21 0.00 0.08 0.09 0.96 0.21 0.00 0.08 0.10 0.97 0.21 -0.01 0.08 0.10 0.96
Cause-specific penetrance (%) given tsc = 35
Cause 1
F1(40;S= 0,G= 0) 2.43 -0.02 0.20 0.21 0.94 2.42 -0.01 0.20 0.21 0.96 2.40 0.00 0.21 0.22 0.95
F1(40;S= 1,G= 0) 3.25 -0.02 0.30 0.31 0.96 3.24 0.00 0.29 0.32 0.97 3.21 0.00 0.31 0.32 0.97
F1(40;S= 0,G= 1) 17.45 -0.02 0.82 0.85 0.96 17.23 0.05 0.87 0.89 0.95 16.27 0.02 1.01 1.01 0.95
F1(40;S= 1,G= 1) 22.47 0.02 1.40 1.42 0.95 22.12 0.12 1.35 1.45 0.96 20.56 0.02 1.41 1.48 0.96
F1(50;S= 0,G= 0) 5.15 -0.04 0.40 0.40 0.95 5.13 -0.02 0.39 0.41 0.96 5.04 0.00 0.42 0.42 0.95
F1(50;S= 1,G= 0) 6.57 -0.03 0.57 0.58 0.95 6.54 -0.01 0.54 0.58 0.96 6.39 0.01 0.57 0.59 0.96
F1(50;S= 0,G= 1) 32.90 -0.03 1.30 1.38 0.96 32.16 0.10 1.43 1.45 0.95 29.06 0.04 1.63 1.65 0.96
F1(50;S= 1,G= 1) 39.48 0.04 2.04 2.05 0.96 38.43 0.16 2.01 2.09 0.95 34.14 0.05 2.03 2.15 0.96
F1(60;S= 0,G= 0) 8.91 -0.07 0.67 0.67 0.94 8.85 -0.03 0.63 0.68 0.96 8.58 0.01 0.68 0.69 0.95
F1(60;S= 1,G= 0) 11.09 -0.06 0.94 0.96 0.95 11.00 -0.03 0.89 0.97 0.96 10.59 -0.01 0.92 0.97 0.96
F1(60;S= 0,G= 1) 48.48 -0.06 1.71 1.84 0.96 46.94 0.15 1.88 1.93 0.95 40.89 0.05 2.12 2.16 0.95
F1(60;S= 1,G= 1) 55.53 -0.04 2.51 2.57 0.95 53.57 0.14 2.50 2.61 0.95 46.03 -0.01 2.50 2.67 0.96
F1(70;S= 0,G= 0) 13.54 -0.10 0.99 1.00 0.95 13.41 -0.04 0.93 1.01 0.97 12.81 0.01 0.98 1.01 0.96
F1(70;S= 1,G= 0) 16.60 -0.11 1.40 1.43 0.94 16.41 -0.06 1.31 1.43 0.95 15.52 -0.02 1.33 1.40 0.96
F1(70;S= 0,G= 1) 61.12 -0.10 1.93 2.09 0.96 58.82 0.18 2.11 2.19 0.95 50.11 0.05 2.38 2.46 0.95
F1(70;S= 1,G= 1) 67.55 -0.13 2.58 2.65 0.95 64.90 0.11 2.60 2.73 0.95 54.88 -0.04 2.69 2.88 0.96
Cause 2
F2(40;S= 0,G= 0) 0.62 0.00 0.09 0.09 0.96 0.62 0.00 0.08 0.09 0.96 0.62 0.00 0.09 0.09 0.96
F2(40;S= 1,G= 0) 0.62 0.00 0.08 0.09 0.96 0.62 0.00 0.08 0.09 0.96 0.62 0.00 0.09 0.09 0.96
F2(40;S= 0,G= 1) 2.66 -0.01 0.22 0.23 0.96 2.67 0.00 0.22 0.23 0.95 2.68 0.01 0.23 0.24 0.96
F2(40;S= 1,G= 1) 2.58 -0.01 0.22 0.22 0.96 2.59 0.00 0.21 0.22 0.95 2.61 0.01 0.22 0.23 0.96
F2(50;S= 0,G= 0) 1.61 0.00 0.20 0.20 0.95 1.61 -0.01 0.19 0.20 0.96 1.61 0.00 0.20 0.21 0.96
F2(50;S= 1,G= 0) 1.59 0.00 0.19 0.20 0.95 1.59 -0.01 0.18 0.20 0.96 1.59 0.00 0.20 0.20 0.95
F2(50;S= 0,G= 1) 6.11 -0.02 0.42 0.42 0.95 6.13 -0.02 0.40 0.42 0.96 6.24 0.02 0.42 0.44 0.96
F2(50;S= 1,G= 1) 5.66 -0.02 0.38 0.39 0.96 5.70 -0.03 0.37 0.39 0.95 5.86 0.01 0.39 0.41 0.96
F2(60;S= 0,G= 0) 3.23 0.01 0.37 0.38 0.95 3.23 -0.03 0.35 0.38 0.96 3.24 0.00 0.37 0.39 0.96
F2(60;S= 1,G= 0) 3.18 0.01 0.37 0.38 0.95 3.18 -0.03 0.34 0.37 0.96 3.18 0.00 0.37 0.38 0.96
F2(60;S= 0,G= 1) 10.30 -0.01 0.68 0.67 0.95 10.42 -0.06 0.64 0.68 0.96 10.90 0.02 0.68 0.73 0.96
F2(60;S= 1,G= 1) 9.22 -0.02 0.62 0.62 0.94 9.37 -0.07 0.60 0.62 0.95 10.00 0.02 0.62 0.67 0.97
F2(70;S= 0,G= 0) 5.53 0.02 0.64 0.65 0.95 5.53 -0.06 0.59 0.65 0.96 5.55 0.00 0.63 0.67 0.97
F2(70;S= 1,G= 0) 5.39 0.02 0.62 0.64 0.95 5.39 -0.06 0.58 0.63 0.96 5.42 0.00 0.61 0.65 0.97
F2(70;S= 0,G= 1) 14.27 0.01 0.97 0.97 0.96 14.61 -0.12 0.93 0.99 0.97 15.91 0.02 1.00 1.10 0.97
F2(70;S= 1,G= 1) 12.35 0.01 0.91 0.91 0.94 12.77 -0.11 0.90 0.93 0.94 14.36 0.02 0.94 1.02 0.97
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Table A.4: (250 families) Empirical properties of the parameter and penetrance estimators for
shared frailty competing risks model with Cox and Oakes TVC under low (k1 = 7), medium
(k1 = 3.5) and high (k1 = 1) familial dependence of the event times for event 1 based on 500
simulations.
Permanent Exposure Model
True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
log(λ1) -4.83 0.00 0.08 0.08 0.95 -4.83 0.00 0.08 0.08 0.94 -4.83 0.00 0.08 0.08 0.94
log(ρ1) 0.88 0.00 0.05 0.05 0.95 0.88 0.00 0.05 0.05 0.93 0.88 0.01 0.05 0.04 0.93
log(λ2) -4.96 -0.01 0.13 0.14 0.96 -4.96 0.00 0.14 0.14 0.94 -4.96 -0.01 0.13 0.14 0.95
log(ρ2) 1.12 0.01 0.10 0.10 0.95 1.12 0.01 0.10 0.10 0.94 1.12 0.01 0.09 0.10 0.93
βs 0.67 0.00 0.16 0.15 0.94 0.67 -0.01 0.15 0.16 0.96 0.67 -0.01 0.16 0.16 0.95
βg1 1.95 -0.01 0.18 0.17 0.93 1.95 0.00 0.16 0.17 0.96 1.95 0.01 0.16 0.16 0.95
βg2 1.19 0.03 0.31 0.33 0.96 1.19 0.02 0.33 0.33 0.96 1.19 0.04 0.33 0.34 0.96
log(k1) 1.95 0.64 2.00 1.30 0.86 1.25 0.29 1.19 0.77 0.94 0.00 0.04 0.38 0.36 0.95
log(k2) 1.06 0.85 2.77 1.63 0.79 1.06 0.84 2.18 1.61 0.78 1.06 0.90 2.73 1.68 0.77
Cause-specific penetrance (%) given tsc = 35
Cause 1
F1(40;S= 0,G= 0) 2.06 0.02 0.39 0.37 0.94 2.05 0.01 0.37 0.38 0.95 2.04 0.00 0.40 0.40 0.93
F1(40;S= 1,G= 0) 2.85 0.04 0.52 0.50 0.93 2.84 0.01 0.49 0.51 0.94 2.81 -0.01 0.54 0.54 0.95
F1(40;S= 0,G= 1) 13.43 -0.09 1.50 1.49 0.94 13.31 0.02 1.63 1.58 0.95 12.72 -0.01 1.86 1.84 0.96
F1(40;S= 1,G= 1) 18.06 -0.03 2.08 2.05 0.94 17.83 0.00 2.20 2.16 0.94 16.80 -0.03 2.45 2.46 0.97
F1(50;S= 0,G= 0) 4.53 0.04 0.78 0.74 0.94 4.52 0.03 0.75 0.76 0.95 4.45 0.02 0.81 0.81 0.94
F1(50;S= 1,G= 0) 7.56 0.12 1.37 1.31 0.92 7.52 0.01 1.25 1.32 0.95 7.32 0.00 1.38 1.38 0.95
F1(50;S= 0,G= 1) 27.07 -0.18 2.59 2.58 0.95 26.56 0.06 2.84 2.77 0.94 24.38 0.10 3.31 3.26 0.96
F1(50;S= 1,G= 1) 40.70 -0.10 4.37 4.33 0.93 39.60 -0.06 4.51 4.51 0.94 35.11 -0.01 4.85 4.87 0.95
F1(60;S= 0,G= 0) 8.07 0.07 1.31 1.27 0.94 8.02 0.06 1.28 1.30 0.95 7.80 0.06 1.37 1.38 0.95
F1(60;S= 1,G= 0) 14.05 0.20 2.43 2.35 0.93 13.91 0.01 2.23 2.36 0.95 13.26 0.02 2.41 2.43 0.95
F1(60;S= 0,G= 1) 42.42 -0.26 3.66 3.69 0.96 41.23 0.12 4.03 3.95 0.93 36.41 0.22 4.70 4.60 0.95
F1(60;S= 1,G= 1) 61.28 -0.29 5.37 5.43 0.94 58.99 -0.14 5.68 5.71 0.94 50.29 0.00 6.24 6.25 0.95
F1(70;S= 0,G= 0) 12.56 0.11 1.98 1.94 0.94 12.45 0.10 1.94 1.98 0.95 11.93 0.12 2.05 2.06 0.95
F1(70;S= 1,G= 0) 21.92 0.27 3.60 3.50 0.94 21.58 0.01 3.31 3.50 0.95 20.09 0.07 3.50 3.53 0.95
F1(70;S= 0,G= 1) 56.52 -0.34 4.40 4.47 0.95 54.51 0.14 4.87 4.79 0.92 46.80 0.29 5.70 5.55 0.94
F1(70;S= 1,G= 1) 75.63 -0.45 5.11 5.26 0.94 72.59 -0.24 5.71 5.71 0.93 61.08 -0.03 6.74 6.72 0.94
Cause 2
F2(40;S= 0,G= 0) 0.46 -0.01 0.15 0.15 0.91 0.46 0.00 0.14 0.15 0.94 0.46 -0.01 0.15 0.15 0.93
F2(40;S= 1,G= 0) 0.46 -0.01 0.14 0.15 0.91 0.46 0.00 0.14 0.15 0.94 0.46 -0.01 0.15 0.15 0.93
F2(40;S= 0,G= 1) 1.40 -0.02 0.29 0.30 0.94 1.41 -0.01 0.31 0.30 0.94 1.41 -0.01 0.31 0.31 0.93
F2(40;S= 1,G= 1) 1.38 -0.02 0.29 0.29 0.94 1.38 -0.01 0.30 0.29 0.94 1.39 -0.01 0.30 0.30 0.93
F2(50;S= 0,G= 0) 1.27 -0.02 0.33 0.34 0.92 1.27 0.00 0.34 0.35 0.93 1.27 -0.02 0.35 0.35 0.94
F2(50;S= 1,G= 0) 1.25 -0.02 0.33 0.34 0.92 1.25 0.00 0.33 0.34 0.93 1.25 -0.02 0.35 0.34 0.94
F2(50;S= 0,G= 1) 3.53 -0.04 0.56 0.59 0.95 3.54 -0.02 0.60 0.60 0.94 3.58 -0.01 0.61 0.63 0.94
F2(50;S= 1,G= 1) 3.21 -0.04 0.51 0.53 0.95 3.23 -0.02 0.55 0.54 0.94 3.31 -0.01 0.55 0.57 0.94
F2(60;S= 0,G= 0) 2.67 -0.03 0.65 0.68 0.93 2.67 0.01 0.67 0.68 0.93 2.67 -0.04 0.69 0.69 0.94
F2(60;S= 1,G= 0) 2.57 -0.03 0.62 0.65 0.94 2.57 0.01 0.65 0.66 0.94 2.58 -0.04 0.66 0.67 0.94
F2(60;S= 0,G= 1) 6.48 -0.04 0.96 1.03 0.95 6.53 -0.01 1.02 1.05 0.95 6.74 0.01 1.08 1.12 0.96
F2(60;S= 1,G= 1) 5.32 -0.04 0.81 0.85 0.95 5.42 -0.01 0.87 0.87 0.95 5.83 0.00 0.91 0.94 0.94
F2(70;S= 0,G= 0) 4.73 -0.03 1.14 1.20 0.95 4.73 0.05 1.20 1.21 0.94 4.74 -0.04 1.20 1.23 0.93
F2(70;S= 1,G= 0) 4.45 -0.04 1.07 1.13 0.94 4.45 0.05 1.13 1.14 0.93 4.49 -0.04 1.13 1.17 0.93
F2(70;S= 0,G= 1) 9.68 -0.01 1.49 1.62 0.97 9.85 0.02 1.60 1.66 0.95 10.52 0.04 1.76 1.81 0.94
F2(70;S= 1,G= 1) 7.12 -0.02 1.18 1.25 0.96 7.42 0.03 1.28 1.30 0.94 8.56 0.03 1.44 1.47 0.95
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Table A.5: (250 families) Empirical properties of the parameter and penetrance estimators for
shared frailty competing risks model with Cox and Oakes TVC under low (k1 = 7), medium
(k1 = 3.5) and high (k1 = 1) familial dependence of the event times for event 1 based on 500
simulations.
Exponential Decay Model
True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
log(λ1) -4.83 0.00 0.08 0.08 0.96 -4.83 -0.01 0.07 0.08 0.98 -4.83 -0.01 0.08 0.08 0.97
log(ρ1) 0.83 0.00 0.04 0.05 0.97 0.83 0.00 0.04 0.05 0.96 0.83 0.00 0.04 0.04 0.95
log(λ2) -4.96 0.00 0.12 0.13 0.96 -4.96 -0.02 0.13 0.13 0.95 -4.96 -0.01 0.13 0.13 0.94
log(ρ2) 1.08 0.01 0.09 0.09 0.95 1.08 0.00 0.09 0.09 0.95 1.08 0.00 0.09 0.09 0.94
βs 1.87 0.02 0.37 0.36 0.93 1.87 0.02 0.34 0.36 0.95 1.87 0.03 0.33 0.34 0.95
βg1 1.86 0.01 0.17 0.17 0.96 1.86 0.02 0.16 0.17 0.97 1.86 0.01 0.16 0.16 0.95
βg2 1.22 0.02 0.30 0.30 0.95 1.22 0.03 0.30 0.30 0.95 1.22 0.04 0.31 0.31 0.95
log(k1) 1.95 0.53 1.86 1.37 0.87 1.25 0.25 0.93 0.78 0.95 0.00 0.04 0.34 0.35 0.96
log(k2) 1.18 0.64 2.16 1.45 0.81 1.18 0.88 2.56 1.62 0.79 1.18 0.78 2.19 1.94 0.80
log(η) -1.28 0.00 0.47 0.45 0.92 -1.28 0.01 0.47 0.45 0.92 -1.28 -0.03 0.44 0.42 0.94
Cause-specific penetrance (%) given tsc = 35
Cause 1
F1(40;S= 0,G= 0) 2.43 -0.01 0.41 0.42 0.94 2.42 -0.02 0.41 0.43 0.94 2.40 0.01 0.43 0.45 0.95
F1(40;S= 1,G= 0) 4.21 -0.02 0.82 0.83 0.93 4.20 -0.04 0.84 0.84 0.95 4.14 0.08 0.84 0.86 0.96
F1(40;S= 0,G= 1) 14.36 -0.06 1.45 1.56 0.97 14.21 0.07 1.62 1.64 0.96 13.55 0.07 1.91 1.87 0.94
F1(40;S= 1,G= 1) 23.47 -0.13 3.27 3.23 0.94 23.09 0.08 3.26 3.28 0.95 21.41 0.33 3.45 3.39 0.94
F1(50;S= 0,G= 0) 5.16 -0.02 0.80 0.82 0.95 5.14 -0.05 0.79 0.83 0.95 5.04 0.02 0.84 0.87 0.96
F1(50;S= 1,G= 0) 7.30 0.07 1.35 1.35 0.93 7.26 0.04 1.35 1.35 0.95 7.08 0.21 1.33 1.39 0.96
F1(50;S= 0,G= 1) 27.84 -0.10 2.42 2.62 0.96 27.30 0.17 2.70 2.77 0.96 25.01 0.10 3.20 3.17 0.95
F1(50;S= 1,G= 1) 36.87 0.22 4.30 4.38 0.96 35.95 0.54 4.38 4.40 0.95 32.16 0.70 4.56 4.58 0.95
F1(60;S= 0,G= 0) 8.91 -0.04 1.33 1.35 0.95 8.85 -0.07 1.29 1.37 0.96 8.59 0.02 1.36 1.43 0.96
F1(60;S= 1,G= 0) 10.98 0.12 1.82 1.82 0.94 10.89 0.08 1.78 1.81 0.96 10.49 0.26 1.76 1.86 0.97
F1(60;S= 0,G= 1) 42.49 -0.15 3.36 3.64 0.97 41.29 0.28 3.71 3.86 0.96 36.44 0.13 4.32 4.36 0.95
F1(60;S= 1,G= 1) 49.34 0.28 4.54 4.71 0.97 47.76 0.74 4.72 4.80 0.95 41.55 0.72 5.12 5.19 0.95
F1(70;S= 0,G= 0) 13.55 -0.05 1.98 2.01 0.96 13.42 -0.08 1.89 2.03 0.96 12.82 0.02 1.97 2.08 0.97
F1(70;S= 1,G= 0) 15.49 0.13 2.37 2.36 0.94 15.32 0.09 2.28 2.36 0.95 14.54 0.27 2.26 2.41 0.98
F1(70;S= 0,G= 1) 55.65 -0.21 4.03 4.36 0.96 53.68 0.36 4.41 4.62 0.95 46.14 0.12 5.08 5.19 0.94
F1(70;S= 1,G= 1) 60.49 0.17 4.61 4.83 0.95 58.24 0.73 4.89 5.03 0.94 49.69 0.61 5.51 5.62 0.94
Cause 2
F2(40;S= 0,G= 0) 0.59 0.00 0.18 0.17 0.92 0.59 0.00 0.17 0.17 0.94 0.59 -0.01 0.18 0.18 0.92
F2(40;S= 1,G= 0) 0.59 0.00 0.18 0.17 0.92 0.59 0.00 0.17 0.17 0.94 0.59 -0.01 0.18 0.17 0.92
F2(40;S= 0,G= 1) 1.86 -0.03 0.35 0.36 0.94 1.86 0.01 0.38 0.36 0.93 1.86 0.00 0.38 0.38 0.93
F2(40;S= 1,G= 1) 1.78 -0.03 0.34 0.34 0.93 1.78 0.00 0.37 0.35 0.93 1.80 0.00 0.36 0.36 0.93
F2(50;S= 0,G= 0) 1.55 -0.01 0.39 0.39 0.94 1.55 -0.02 0.38 0.39 0.95 1.56 -0.03 0.40 0.40 0.92
F2(50;S= 1,G= 0) 1.52 -0.01 0.39 0.38 0.93 1.53 -0.02 0.37 0.38 0.94 1.53 -0.03 0.39 0.39 0.92
F2(50;S= 0,G= 1) 4.42 -0.05 0.66 0.67 0.94 4.44 -0.02 0.72 0.69 0.94 4.49 0.00 0.74 0.72 0.94
F2(50;S= 1,G= 1) 3.99 -0.06 0.59 0.60 0.95 4.02 -0.03 0.64 0.61 0.94 4.12 -0.02 0.65 0.65 0.95
F2(60;S= 0,G= 0) 3.14 -0.01 0.73 0.75 0.94 3.14 -0.04 0.72 0.75 0.94 3.14 -0.05 0.75 0.76 0.93
F2(60;S= 1,G= 0) 3.07 -0.01 0.71 0.73 0.94 3.07 -0.04 0.70 0.73 0.94 3.07 -0.05 0.73 0.74 0.93
F2(60;S= 0,G= 1) 7.81 -0.05 1.09 1.13 0.94 7.87 -0.06 1.16 1.15 0.94 8.13 0.01 1.23 1.23 0.94
F2(60;S= 1,G= 1) 6.90 -0.09 0.95 1.00 0.94 6.99 -0.10 1.03 1.01 0.94 7.38 -0.06 1.07 1.09 0.94
F2(70;S= 0,G= 0) 5.39 0.01 1.23 1.28 0.95 5.39 -0.06 1.23 1.28 0.94 5.41 -0.07 1.29 1.31 0.93
F2(70;S= 1,G= 0) 5.26 0.00 1.20 1.25 0.95 5.26 -0.07 1.20 1.25 0.94 5.28 -0.08 1.25 1.28 0.93
F2(70;S= 0,G= 1) 11.38 -0.03 1.66 1.71 0.94 11.57 -0.12 1.69 1.74 0.95 12.34 0.01 1.87 1.93 0.95
F2(70;S= 1,G= 1) 9.97 -0.10 1.45 1.53 0.95 10.22 -0.19 1.51 1.55 0.95 11.20 -0.10 1.66 1.74 0.94
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Table A.6: (250 families) Empirical properties of the parameter and penetrance estimators for
shared frailty competing risks model with Cox and Oakes TVC under low (k1 = 7), medium
(k1 = 3.5) and high (k1 = 1) familial dependence of the event times for event 1 based on 500
simulations.
Cox and Oakes Model
True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
log(λ1) -4.83 0.00 0.07 0.08 0.95 -4.83 0.00 0.07 0.08 0.96 -4.83 0.00 0.07 0.09 0.95
log(ρ1) 0.83 0.01 0.04 0.05 0.96 0.83 0.00 0.04 0.05 0.94 0.83 0.01 0.04 0.05 0.95
log(λ2) -4.96 -0.01 0.11 0.13 0.95 -4.96 -0.01 0.11 0.13 0.94 -4.96 0.01 0.10 0.12 0.94
log(ρ2) 1.07 0.00 0.08 0.09 0.94 1.07 0.00 0.07 0.09 0.96 1.07 0.01 0.07 0.08 0.96
βs 1.52 0.11 0.47 0.61 0.94 1.52 0.05 0.48 0.57 0.93 1.52 0.10 0.48 0.57 0.93
βg1 2.08 0.03 0.14 0.17 0.95 2.08 0.01 0.15 0.17 0.95 2.08 0.01 0.14 0.16 0.96
βg2 1.57 0.03 0.24 0.29 0.96 1.57 0.02 0.24 0.29 0.97 1.57 0.02 0.26 0.30 0.96
log(k1) 1.95 0.26 0.99 1.13 0.89 1.25 0.12 0.58 0.72 0.95 0.00 0.03 0.27 0.32 0.97
log(k2) 1.26 0.57 1.52 1.55 0.82 1.26 0.57 1.44 1.63 0.81 1.26 0.67 1.51 1.76 0.81
log(η) -0.18 -0.01 0.71 0.80 0.87 -0.18 -0.07 0.69 0.82 0.87 -0.18 -0.13 0.68 0.77 0.87
η0 0.21 -0.03 0.17 0.21 0.95 0.21 -0.03 0.17 0.21 0.96 0.21 -0.05 0.19 0.22 0.94
Cause-specific penetrance (%) given tsc = 35
Cause 1
F1(40;S= 0,G= 0) 2.43 -0.04 0.39 0.40 0.94 2.42 -0.02 0.41 0.42 0.94 2.40 0.01 0.41 0.43 0.95
F1(40;S= 1,G= 0) 3.25 0.00 0.58 0.63 0.95 3.24 0.02 0.62 0.65 0.95 3.21 0.10 0.62 0.66 0.95
F1(40;S= 0,G= 1) 17.45 -0.03 1.73 1.69 0.94 17.23 -0.12 1.70 1.78 0.95 16.27 0.09 1.94 2.01 0.95
F1(40;S= 1,G= 1) 22.47 0.30 2.82 2.85 0.97 22.12 0.16 2.80 2.93 0.95 20.56 0.54 2.78 3.01 0.98
F1(50;S= 0,G= 0) 5.15 -0.07 0.77 0.80 0.95 5.13 -0.04 0.79 0.82 0.95 5.04 0.03 0.81 0.85 0.96
F1(50;S= 1,G= 0) 6.57 -0.02 1.09 1.16 0.94 6.54 0.02 1.15 1.18 0.95 6.39 0.10 1.14 1.20 0.95
F1(50;S= 0,G= 1) 32.90 0.05 2.77 2.74 0.94 32.16 -0.14 2.72 2.91 0.97 29.06 0.21 3.13 3.29 0.96
F1(50;S= 1,G= 1) 39.48 0.33 4.15 4.15 0.94 38.43 0.12 4.15 4.26 0.95 34.14 0.42 4.05 4.34 0.95
F1(60;S= 0,G= 0) 8.91 -0.09 1.27 1.33 0.96 8.85 -0.06 1.31 1.36 0.95 8.58 0.07 1.33 1.39 0.96
F1(60;S= 1,G= 0) 11.09 -0.12 1.82 1.91 0.93 11.00 -0.08 1.87 1.96 0.95 10.59 -0.01 1.85 1.93 0.96
F1(60;S= 0,G= 1) 48.48 0.11 3.55 3.65 0.95 46.94 -0.14 3.57 3.88 0.97 40.89 0.30 4.07 4.32 0.96
F1(60;S= 1,G= 1) 55.53 -0.05 5.06 5.10 0.95 53.57 -0.25 5.05 5.31 0.96 46.03 0.02 4.99 5.31 0.96
F1(70;S= 0,G= 0) 13.54 -0.09 1.88 2.00 0.96 13.41 -0.07 1.93 2.02 0.95 12.81 0.12 1.94 2.03 0.96
F1(70;S= 1,G= 0) 16.60 -0.27 2.70 2.85 0.93 16.41 -0.22 2.72 2.89 0.96 15.52 -0.15 2.68 2.80 0.95
F1(70;S= 0,G= 1) 61.12 0.10 3.87 4.12 0.96 58.82 -0.13 4.06 4.42 0.97 50.11 0.31 4.62 4.91 0.96
F1(70;S= 1,G= 1) 67.55 -0.40 5.15 5.28 0.95 64.90 -0.50 5.22 5.59 0.96 54.88 -0.26 5.42 5.75 0.96
Cause 2
F2(40;S= 0,G= 0) 0.62 0.00 0.18 0.18 0.93 0.62 -0.01 0.17 0.17 0.94 0.62 0.01 0.18 0.18 0.93
F2(40;S= 1,G= 0) 0.62 0.00 0.18 0.18 0.93 0.62 -0.01 0.17 0.17 0.94 0.62 0.01 0.18 0.18 0.93
F2(40;S= 0,G= 1) 2.66 0.00 0.45 0.46 0.94 2.67 -0.03 0.45 0.46 0.95 2.68 0.02 0.48 0.48 0.92
F2(40;S= 1,G= 1) 2.58 -0.01 0.43 0.44 0.94 2.59 -0.03 0.43 0.45 0.96 2.61 0.02 0.46 0.46 0.92
F2(50;S= 0,G= 0) 1.61 -0.01 0.39 0.40 0.93 1.61 -0.02 0.39 0.40 0.95 1.61 0.03 0.41 0.41 0.93
F2(50;S= 1,G= 0) 1.59 -0.01 0.39 0.39 0.93 1.59 -0.02 0.38 0.39 0.94 1.59 0.02 0.40 0.40 0.93
F2(50;S= 0,G= 1) 6.11 -0.02 0.81 0.83 0.94 6.13 -0.06 0.83 0.84 0.95 6.24 0.06 0.89 0.89 0.94
F2(50;S= 1,G= 1) 5.66 -0.04 0.74 0.77 0.95 5.70 -0.08 0.76 0.78 0.95 5.86 0.03 0.81 0.82 0.94
F2(60;S= 0,G= 0) 3.23 -0.02 0.73 0.76 0.94 3.23 -0.03 0.74 0.76 0.95 3.24 0.06 0.77 0.79 0.94
F2(60;S= 1,G= 0) 3.18 -0.02 0.72 0.74 0.94 3.18 -0.04 0.73 0.74 0.95 3.18 0.06 0.76 0.77 0.94
F2(60;S= 0,G= 1) 10.30 -0.03 1.31 1.34 0.95 10.42 -0.06 1.34 1.36 0.95 10.90 0.13 1.42 1.46 0.95
F2(60;S= 1,G= 1) 9.22 -0.06 1.19 1.23 0.96 9.37 -0.09 1.22 1.25 0.95 10.00 0.09 1.28 1.34 0.96
F2(70;S= 0,G= 0) 5.53 -0.03 1.23 1.29 0.94 5.53 -0.04 1.28 1.30 0.94 5.55 0.13 1.31 1.35 0.95
F2(70;S= 1,G= 0) 5.39 -0.03 1.19 1.26 0.94 5.39 -0.04 1.24 1.27 0.94 5.42 0.13 1.28 1.31 0.94
F2(70;S= 0,G= 1) 14.27 -0.04 1.89 1.93 0.95 14.61 -0.05 1.96 1.98 0.95 15.91 0.20 2.10 2.19 0.96
F2(70;S= 1,G= 1) 12.35 -0.03 1.77 1.82 0.95 12.77 -0.04 1.82 1.87 0.94 14.36 0.19 1.95 2.06 0.95
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Figure A.1: (1000 families) Boxplot of bias of the model parameters for PE TVC model under
low (k1 = 7), medium (k1 = 3.5) and high (k1 = 1) familial dependence of the event times for
event 1.
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Figure A.2: (1000 families) Boxplot of bias of the model parameters for ED TVC model under
low (k1 = 7), medium (k1 = 3.5) and high (k1 = 1) familial dependence of the event times for
event 1.
Figure A.3: (1000 families) Boxplot of bias of the model parameters for CO TVC model under
low (k1 = 7), medium (k1 = 3.5) and high (k1 = 1) familial dependence of the event times for
event 1.
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Figure A.4: (1000 families) Boxplot of bias of the frailty parameters for PE TVC model under
low (k1 = 7), medium (k1 = 3.5) and high (k1 = 1) familial dependence of the event times for
event 1.
Figure A.5: (1000 families) Boxplot of bias of the frailty parameters for ED TVC model under
low (k1 = 7), medium (k1 = 3.5) and high (k1 = 1) familial dependence of the event times for
event 1.
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Figure A.6: (1000 families) Boxplot of bias of the frailty parameters for CO TVC model under
low (k1 = 7), medium (k1 = 3.5) and high (k1 = 1) familial dependence of the event times for
event 1.
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Figure A.7: Bias and precision of the parameter estimates for mutation effect parameter for
event 2, βg,1, expressed as mean +/- 1.96ASE, based on 500 simulations. True value of the βg,2
is 1.194 for PE, 1.224 for ED and 1.566 for CO.
Appendix B
R codes
# FITTING MODEL CODES
FitModelEM <- function( data = data,
init.Parms = list(
cause1 = list(base = c(0.008,2.581), time_indep=c(2.084), time_dep=list(main=c(2.364,1.033,1.128,0.411)),
cause2 = list(base = c(0.006,2.538), time_indep=c(1.437), time_dep=list(main=0.818)),
cause3 = list(base = c(0.016,4.193), time_indep=c(-0.094), time_dep=list(main=-1.851))
),
time.dep.cov = list(time.dep.cov.type = "PE" , # "ED")
reccur.type = "IS" # "CM")
),
missing.method = "data",
base.dist = "Weibull",
frailty=FALSE,
weight=FALSE,
mutation.prediction=FALSE
){
#initial parameters
base.parms <- c(init.Parms[[1]]$base, init.Parms[[2]]$base, init.Parms[[3]]$base)
# total 6, lambda1,rho1 lambda2,rho2, lambda3,rho3
vbeta_b <- c( init.Parms[[1]]$time_indep, init.Parms[[1]]$time_dep$main, init.Parms[[1]]$time_dep$interaction )
# breast cancer parameter
vbeta_o <- c( init.Parms[[2]]$time_indep, init.Parms[[2]]$time_dep$main )
# ovarian cancer parameter
vbeta_d <- c( init.Parms[[3]]$time_indep, init.Parms[[3]]$time_dep$main )
# death parameter
vbeta <- c(vbeta_b,vbeta_o,vbeta_d)
tvctype=time.dep.cov$time.dep.cov.type
if(tvctype=="ED"){
phi_sc=c(log(c(0.5,0.5,0.5)))
phi_or=c(log(0.5))
} else if (tvctype=="CO"){
phi_sc=c(log(c(0.5,0.5,0.5)))
phi_or=c(log(0.5),0)
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} else if (tvctype=="PE"){
phi_sc=c(log(c(0.5,0.5,0.5)))
phi_or=NULL
} else if (tvctype=="TIC"){
phi_sc=c(log(c(0.5,0.5,0.5)))
phi_or=NULL
}
if(frailty==TRUE){
datacopy = data
fsize <- aggregate(datacopy$status, by=list(datacopy$famID), length)[,2]
df1 <- aggregate(datacopy$status==1, by=list(datacopy$famID), FUN=sum)[,2]
df2 <- aggregate(datacopy$status==3, by=list(datacopy$famID), FUN=sum)[,2]
#df3 <- aggregate(datacopy$status==4, by=list(datacopy$famID), FUN=sum)[,2]
data$df1 <- rep(df1, fsize)
data$df2 <- rep(df2, fsize)
#data$df3 <- rep(df3, fsize)
fp <- c(3.5, 3.5)#, 3.5)
} else {
fp = NULL
}
theta = c(log(base.parms),vbeta,phi_sc,phi_or,log(fp)) # length(theta) = 14
# data preparation
data2 <- Data_preparation(data)
# Imputing Missing mutation status
data.cooked = carrierprobgeno(method = missing.method, data=data)
impute=function(dat){
for(i in 1:nrow(dat)){
if(is.na(dat$mgene[i]))dat[i,"mgene"]<-sample(c(0,1),1,prob=c(1-dat$carrp.geno[i],dat$carrp.geno[i]),replace=TRUE)
}
return(dat)
}
data.cooked = impute(data.cooked)
est0 <- est <- theta
est1 <- optim(est, loglik_Comp_Timedep, data=data.cooked, data2=data2,
agemin=16, frailty=TRUE,
tvctype = tvctype,
hessian=TRUE, control=list(maxit=10000))
print(est1$convergence)
return(est1)
}
# Logliklihood function
loglik_Comp_Timedep=function(theta, data, data2, agemin, frailty=FALSE, tvctype){
data = data[data$currentage>=agemin,]
# base parameters
lambda1 = exp(theta[1]);rho1 = exp(theta[2]);lambda2 = exp(theta[3]);rho2 = exp(theta[4])
lambda3 = exp(theta[5]);rho3 = exp(theta[6])
# vbeta for breast
beta.gen1 = theta[7];beta.sc1_1 = theta[8];beta.sc2_1 = theta[9];beta.sc3_1 = theta[10]
beta.or1 = theta[11]
# vbeta for ovarian
beta.gen2 = theta[12]
# vbeta for death
beta.gen3 = theta[13]
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# time varying covariate type
if(tvctype=="ED"){
phi_sc = c(exp(theta[14:16]),0,0,0) #ED
phi_or = c(exp(theta[17]),0)
}else if(tvctype=="CO"){
phi_sc = c(exp(theta[14:16]),0,0,0) #ED
phi_or = c(exp(theta[17]),theta[18]) #CO
}else if(tvctype=="PE"){
phi_sc = c(exp(theta[14:16]),0,0,0) #ED
phi_or = c(0,0)
}else if(tvctype=="TIC"){
phi_sc = c(exp(theta[14:16]),0,0,0)
phi_or = c(0,0)
}
# frailty parameter
if(frailty==TRUE){
fp <- exp(theta[(length(theta)-1):length(theta)])
}else{
fp=NULL
}
# Y, delta, carrier prob, proband indicator, sc number
time0 = data$time-agemin
status = data$status
ip = which(data$proband==1)
mgene=data$mgene
sc_num = data$screen_number
sc_num_p = data$screen_number_p
#setting up indicator variable for the removal status
br_time <- data$br.censortime-agemin
delta_BR <- ifelse(time0-br_time > 0,1,0)
sc1_time <- data$st1 - agemin
sc2_time <- data$st2 - agemin
sc3_time <- data$st3 - agemin
Z_SC1= ifelse(is.na(sc1_time), 0,1)
Z_SC2= ifelse(is.na(sc2_time), 0,1)
Z_SC3= ifelse(is.na(sc3_time), 0,1)
# Variables related to oophorectomy
ov_time <- data$ov.censortime-agemin
delta_OR <- ifelse(time0-ov_time > 0,1,0)
Z_OR <- rep(1,nrow(data))
if(tvctype!="TIC"){
Z_OR = ifelse( delta_OR==0, 0, ZED(time0, ov_time, phi_or[1]))
Z_SC1 = ifelse( Z_SC1==0, 0, ZED(time0, sc1_time, phi_sc[1]))
Z_SC2 = ifelse( Z_SC2==0, 0, ZED(time0, sc2_time, phi_sc[2]))
Z_SC3 = ifelse( Z_SC3==0, 0, ZED(time0, sc3_time, phi_sc[3]))
}
#loading up event time(sorted) vectors, event indicator vectors
time_vec2 <- data2[[1]]
indicator_vec <- data2[[2]]
time_vec2_p0 <- data2[[3]]
indicator_vec_p0 <- data2[[4]]
time_vec2_p1 <- data2[[5]]
indicator_vec_p1 <- data2[[6]]
time_vec2_p2 <- data2[[7]]
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indicator_vec_p2 <- data2[[8]]
# baseline hazard(weibull), baseline cumulative hazard(weibull)
bhaz1 = (lambda1ˆrho1)*rho1*time0ˆ(rho1-1)
bcumhaz1 = (lambda1*time0)ˆrho1
bhaz2 = (lambda2ˆrho2)*rho2*time0ˆ(rho2-1)
bcumhaz2 = (lambda2*time0)ˆrho2
bhaz3 = (lambda3ˆrho3)*rho3*time0ˆ(rho3-1)
bcumhaz3 = (lambda3*time0)ˆrho3
logh1 = log(bhaz1) + mgene*beta.gen1 ###
logh2 = log(bhaz2) + mgene*beta.gen2
logh3 = log(bhaz3) + mgene*beta.gen3
# creating screen,gene,oophorectomy interaction vectors for hazard
sc_vec <-rep(0,nrow(data))
sc_vec[sc_num==0] <- 0
sc_vec[sc_num!=0] <- sc_num[sc_num!=0]
sc_vec_bc <- vector("numeric", length(sc_num) )
sc_vec_bc[sc_vec==0] <- 0
sc_vec_bc[sc_vec==1] <- Z_SC1[sc_vec==1]*beta.sc1_1 + phi_sc[4]
sc_vec_bc[sc_vec==2] <- Z_SC2[sc_vec==2]*beta.sc2_1 + phi_sc[5]
sc_vec_bc[sc_vec==3] <- Z_SC3[sc_vec==3]*beta.sc3_1 + phi_sc[6]
# sum of log-hazard
sum1 = sum((logh1+ (delta_OR*Z_OR*beta.or1 + delta_OR*phi_or[2]) + sc_vec_bc)[status==1], na.rm=TRUE)
if(tvctype=="TIC"){
sum1 = sum((logh1+ (delta_OR*beta.or1) + sc_vec_bc)[status==1], na.rm=TRUE)
}
sum2 = sum(logh2[status==3], na.rm=TRUE)
sum3 = sum(logh3[status==4], na.rm=TRUE)
# sum of survival until event time for all the individuals in the data
cest <- c(lambda1,rho1,lambda2,rho2,lambda3,rho3,beta.gen1,beta.sc1_1,beta.sc2_1,
beta.sc3_1,beta.or1,beta.gen2,beta.gen3)
mat_all <- cbind(time_vec2, indicator_vec, time0, mgene)
if(tvctype \%in\% c("PE","ED","CO")){
testm <- mat_p1
testm[is.na(testm)] <- 99
CH_bc=CumH_c_CO(v1= testm[,1:5], v2=testm[,6:10], u = testm[,11],cest=cest, affp=FALSE, type=1,phi=phi_sc,phi2=phi_or)
CH_ov=CumH_c_CO(v1= testm[,1:5], v2=testm[,6:10], u = testm[,11],cest=cest, affp=FALSE, type=2,phi=phi_sc,phi2=phi_or)
CH_d=CumH_c_CO(v1= testm[,1:5], v2=testm[,6:10], u = testm[,11],cest=cest, affp=FALSE, type=3,phi=phi_sc,phi2=phi_or)
}
if(tvctype=="TIC"){
CH_bc <- exp(testm[,12]*beta.gen1+delta_OR*beta.or1)*CH_bc[,1]
}else{
CH_bc <- exp(testm[,12]*beta.gen1)*CH_bc[,1]
}
CH_ov <- exp(testm[,12]*beta.gen2)*CH_ov[,1]
CH_d <- exp(testm[,12]*beta.gen3)*CH_d[,1]
k <- CH_bc + CH_ov + CH_d
sum4=k
if(frailty==TRUE){ # Gamma-frailty
Hfam1 <- -CH_bc
Hfam2 <- -CH_ov
Hfam3 <- -CH_d
df1 <- data$df1[data$proband==1]
df2 <- data$df2[data$proband==1]
df3 <- data$df3[data$proband==1]
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Hfam1 <- aggregate(Hfam1,by=list(data$famID),FUN=sum)[,2]
Hfam2 <- aggregate(Hfam2,by=list(data$famID),FUN=sum)[,2]
Hfam3 <- aggregate(Hfam3,by=list(data$famID),FUN=sum)[,2]
sum4.1 <- sum((lfactorial(fp[1]+df1-1)-(df1-1)*log(fp[1])-lfactorial(fp[1]) +
(-fp[1]-df1)*log(1+(Hfam1)/fp[1])), na.rm=T)
sum4.2 <- sum((lfactorial(fp[2]+df2-1)-(df2-1)*log(fp[2])-lfactorial(fp[2]) +
(-fp[2]-df2)*log(1+(Hfam2)/fp[2])), na.rm=T)
#sum4.3 <- sum((lfactorial(fp[3]+df3-1)-(df3-1)*log(fp[3])-lfactorial(fp[3]) +
(-fp[3]-df3)*log(1+(Hfam3)/fp[3])), na.rm=T)
loglik = sum1+sum2+sum3+sum4.1+sum4.2+sum(Hfam3,na.rm=TRUE)
}else{
sum4 <- sum(sum4,na.rm = TRUE)
loglik = sum1+sum2+sum3+sum4 # numerator in loglikelihood
}
# Ascertainment correction by design="pop+"
cagep <- data$currentage[ip]-agemin
timep <- data$time[ip]-agemin
statusp <- data$affect[ip] # proband disease status at the study entry
# subsetting the probands according to his affection status at study entry
cagep0 <- cagep[statusp==0]
timep0 <- timep[statusp==0]
mat_p0 <- cbind(time_vec2_p0, indicator_vec_p0, cagep0)
if(tvctype \%in\% c("PE","ED","CO")){
testm <- mat_p1
testm[is.na(testm)] <- 99
CH_bc=CumH_c_CO(v1= testm[,1:5], v2=testm[,6:10], u = testm[,11],cest=cest, affp=FALSE, type=1,phi=phi_sc,phi2=phi_or)
CH_ov=CumH_c_CO(v1= testm[,1:5], v2=testm[,6:10], u = testm[,11],cest=cest, affp=FALSE, type=2,phi=phi_sc,phi2=phi_or)
CH_d=CumH_c_CO(v1= testm[,1:5], v2=testm[,6:10], u = testm[,11],cest=cest, affp=FALSE, type=3,phi=phi_sc,phi2=phi_or)
}
if(tvctype=="TIC"){
CH1_bc <- exp(beta.gen1+delta_OR[ip][statusp==0]*beta.or1)*CH_bc[,1]
}else{
CH1_bc <- exp(beta.gen1)*CH_bc[,1]
}
CH1_ov <- exp(beta.gen2)*CH_ov[,1]
CH1_d <- exp(beta.gen3)*CH_d[,1]
logasc0 <- CH1_bc + CH1_ov +CH1_d
if(frailty==TRUE){
logS <- log((1-CH1_bc/fp[1])ˆ(-fp[1])) + log((1-CH1_ov/fp[2])ˆ(-fp[2])) + CH1_d
}else {
logS <- logasc0
}
logasc0 <- sum(logS,na.rm=TRUE)
# subsetting the probands according to his affection status at study entry
cagep1 <- cagep[statusp==1|statusp==2]
timep1 <- timep[statusp==1|statusp==2]
mat_p1 <- cbind(time_vec2_p1, indicator_vec_p1, cagep1)
if(tvctype \%in\% c("PE","ED","CO")){
testm <- mat_p1
testm[is.na(testm)] <- 99
CH_bc=CumH_c_CO(v1= testm[,1:5], v2=testm[,6:10], u = testm[,11],cest=cest, affp=FALSE, type=1,phi=phi_sc,phi2=phi_or)
CH_ov=CumH_c_CO(v1= testm[,1:5], v2=testm[,6:10], u = testm[,11],cest=cest, affp=FALSE, type=2,phi=phi_sc,phi2=phi_or)
CH_d=CumH_c_CO(v1= testm[,1:5], v2=testm[,6:10], u = testm[,11],cest=cest, affp=FALSE, type=3,phi=phi_sc,phi2=phi_or)
}
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if(tvctype=="TIC"){
CH1_bc <- exp(beta.gen1+delta_OR[ip][statusp==1|statusp==2]*beta.or1)*CH_bc[,1]
}else{
CH1_bc <- exp(beta.gen1)*CH_bc[,1]
}
CH1_ov <- exp(beta.gen2)*CH_ov[,1]
CH1_d <- exp(beta.gen3)*CH_d[,1]
if(frailty==TRUE){
logS <- log(1-((1-CH1_bc/fp[1])ˆ(-fp[1]))*((1-CH1_ov/fp[2])ˆ(-fp[2]))*exp(CH1_d))
}else {
logS <- log(1-exp(CH1_bc+CH1_ov) )
}
logasc12=sum(logS,na.rm=TRUE)
slogasc = logasc0 + logasc12
likelihood <- loglik - slogasc
return(-likelihood)
}
#C++ and R integrated function via Rcpp package for numerical integration of hazard function
#from the matrix of individuals timeline information of Screens and surgeries history
NumericMatrix CumH_c_CO(NumericMatrix v1, NumericMatrix v2, NumericVector u, NumericVector cest,
bool affp, int type, NumericVector phi, NumericVector phi2) {
int n = v1.nrow();
NumericMatrix Hvec(n,1);
NumericVector uv = u;
for(int j=0; j < n; ++j) {
double finalH=0;
double phisc=0, phior=0, phior0=0, phisc0=0;
double u = uv[j];
NumericVector k1 = v1( j , _ );
NumericVector k2 = k1[k1<u];
int size = k2.size();
if (size==0) {
// double chaz(double lam1, double rho1, double betasc, double betaor, double phisc, double phior,
// double lowsc, double lowor, double low, double upper)
if(type==1){
finalH = -chaz(cest[0],cest[1],0,0,0,0, 0,0, 0,u);
} else if (type==2){
finalH = -chaz(cest[2],cest[3],0,0,0,0, 0,0, 0,u);
} else if (type==3){
finalH = -chaz(cest[4],cest[5],0,0,0,0, 0,0, 0,u);
}
} else {
k2.push_back(u);
size = k2.size();
NumericVector w2 = v2( j , _ );
NumericVector Hfull;
double beta_sc=0, beta_or=0, lowsc=0, lowor=0;
for (int i=0; i < size; ++i) {
double beta;
if(i!=0){
beta = coeff_c_CO(w2[i-1],type=type, affp, cest);
if(w2[i-1]==1 || w2[i-1]==2 || w2[i-1]==3 ){
beta_sc = beta;
90 CHAPTER B. R CODES
phisc = phi[w2[i-1]-1];
phisc0 = phi[w2[i-1]+2];
lowsc = k2[i-1];
}else if(w2[i-1]==4){
beta_or = beta;
lowor = k2[i-1];
if(type==1){
phior=phi2[0];
phior0=phi2[1];
}
}
}else{
beta = 0;
beta_sc = beta;
beta_or = beta;
}
if(beta==99){
break;
}
double Hpiece, H_noncarrier, low, upper;
upper = k2[i];
if(i!=0){
low = k2[i-1];
} else{
low = 0;
}
// double chaz(double lam1, double rho1, double betasc, double betaor, double phisc, double phior,
// double lowsc, double lowor, double low, double upper)
if(type==1){
Hpiece = chaz(cest[0],cest[1],beta_sc,beta_or,phisc,phior,lowsc=lowsc,lowor=lowor, low=low,upper=upper);
Hpiece = Hpiece*exp(phisc0+phior0);
} else if (type==2){
Hpiece = chaz(cest[2],cest[3],0,0,0,0, 0,0, low=low,upper=upper);
} else {
Hpiece = chaz(cest[4],cest[5],0,0,0,0, 0,0, low=low,upper=upper);
}
H_noncarrier = Hpiece;
Hfull.push_back(H_noncarrier);
}
finalH = -sum(Hfull);
}
Hvec(j,0) = finalH;
}
return Hvec;
}
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